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Guest-Host Interactions To Engineer Injectable Hydrogels With Controlled
Degradation And Release For Cardiac Repair
Abstract
Guest-host chemistry is an emerging tool in the preparation of biomaterials. Towards the design of
hydrogels, guest-host chemistry has been used to impart unique shear-thinning and self-healing
properties that allow these materials to be injected through syringes and catheters as a single
component, avoiding complications associated with traditional covalent systems. As a treatment for
myocardial infarction, injectable guest-host hydrogels may be injected directly into the myocardial wall
and have shown therapeutic benefit in a number of strategies, including drug delivery, cell delivery, and
tissue bulking. As delivery systems, injectable hydrogels provide controlled release of payloads that
attenuate maladaptive remodeling of the left ventricle, by inhibiting expression of proteases, recruiting
cells to the region, or otherwise stimulating therapeutic biological processes such as angiogenesis.
Guest-host biomaterials must be refined and advanced to overcome challenges associated with
delivering therapeutics in these areas, as well as to provide novel materials platforms for investigating
therapeutic delivery in the future. This dissertation describes the engineering of two injectable hydrogel
platforms that address challenges in the delivery of therapeutics after myocardial infarction. Each of
these systems is investigated both in vitro for an understanding of material properties and the
parameters that tune them, as well as in vivo, in a number of clinically relevant animal models and
therapeutic targets. In the first aim of this thesis, isotropic guest-host hydrogels are designed for the
sustained release of a variety of small molecules. Through the control of small molecule binding with
cyclodextrin host moieties engineered in the hydrogel, we show that both cyclodextrin content and
molecule affinity for cyclodextrin are critical factors that provide tunable release of small molecules from
these systems. Furthermore, we demonstrate that this system is broadly applicable to the release of a
number of pharmaceutical small molecule payloads. In the second aim of this thesis, isotropic guest-host
hydrogels are specifically formulated for the delivery of the small molecule protease inhibitor SD-7300, a
therapeutic requiring local delivery after myocardial infarction. Here we demonstrate that the engineered
guest-host hydrogels provide sustained release and retain activity of this molecule, which in turn provides
improved functional and biological outcomes in a large-animal model of myocardial infarction. In the third
aim of this thesis, guest-host chemistry is utilized to assemble microstructured granular hydrogels for the
design of multifunctional material platforms. Granular hydrogels are demonstrated to have disease
responsivity in myocardial infarction, and functional benefit through the delivery of the chemokine
SDF-1α.
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ABSTRACT

GUEST-HOST INTERACTIONS TO ENGINEER INJECTABLE HYDROGELS WITH
CONTROLLED DEGRADATION AND RELEASE FOR CARDIAC REPAIR
Joshua E. Mealy
Jason A. Burdick, Ph.D.
Guest-host chemistry is an emerging tool in the preparation of biomaterials.
Towards the design of hydrogels, guest-host chemistry has been used to impart unique
shear-thinning and self-healing properties that allow these materials to be injected
through syringes and catheters as a single component, avoiding complications
associated with traditional covalent systems. As a treatment for myocardial infarction,
injectable guest-host hydrogels may be injected directly into the myocardial wall and
have shown therapeutic benefit in a number of strategies, including drug delivery, cell
delivery, and tissue bulking. As delivery systems, injectable hydrogels provide controlled
release of payloads that attenuate maladaptive remodeling of the left ventricle, by
inhibiting expression of proteases, recruiting cells to the region, or otherwise stimulating
therapeutic biological processes such as angiogenesis. Guest-host biomaterials must be
refined and advanced to overcome challenges associated with delivering therapeutics in
these areas, as well as to provide novel materials platforms for investigating therapeutic
delivery in the future.
This dissertation describes the engineering of two injectable hydrogel platforms
that address challenges in the delivery of therapeutics after myocardial infarction. Each
of these systems is investigated both in vitro for an understanding of material properties
and the parameters that tune them, as well as in vivo, in a number of clinically relevant
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animal models and therapeutic targets.
In the first aim of this thesis, isotropic guest-host hydrogels are designed for the
sustained release of a variety of small molecules. Through the control of small molecule
binding with cyclodextrin host moieties engineered in the hydrogel, we show that both
cyclodextrin content and molecule affinity for cyclodextrin are critical factors that provide
tunable release of small molecules from these systems. Furthermore, we demonstrate
that this system is broadly applicable to the release of a number of pharmaceutical small
molecule payloads.
In the second aim of this thesis, isotropic guest-host hydrogels are specifically
formulated for the delivery of the small molecule protease inhibitor SD-7300, a
therapeutic requiring local delivery after myocardial infarction. Here we demonstrate that
the engineered guest-host hydrogels provide sustained release and retain activity of this
molecule, which in turn provides improved functional and biological outcomes in a largeanimal model of myocardial infarction.
In the third aim of this thesis, guest-host chemistry is utilized to assemble
microstructured granular hydrogels for the design of multifunctional material platforms.
Granular hydrogels are demonstrated to have disease responsivity in myocardial
infarction, and functional benefit through the delivery of the chemokine SDF-1α.
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CHAPTER 1
INTRODUCTION
1.1. SIGNIFICANCE
Cardiovascular disease accounts for 17.3 million deaths annually and is the
leading cause of death across the globe; within cardiovascular diseases, ischemic heart
disease is the most deadly.1,2 Specifically, almost one in four deaths in the United
States, or 610,000 individuals die every year of heart disease.3 Myocardial infarction (MI)
is among the most prominent and lethal types of heart disease, affecting 735,000
Americans annually. MI occurs after an occlusion of the coronary artery disrupts the
normal perfusion of the myocardium (Figure 1.1). This ischemic event leads to cell
necrosis and inflammation, including the loss of cardiomyocytes - the contractile cell of
the heart.

	
  	
  
Figure 1.1. Schematic representation of myocardial infarction. Plaque buildup within
a coronary artery ruptures, leading to thrombus formation and occlusion of the vessel.
Ischemia as a result of this occlusion leads to muscle damage in the myocardial tissue.
Adapted from Bax et al.4
As an immediate treatment, interventions are focused on restoring blood flow (i.e.
repurfusion) to the myocardium through biochemical approaches such as fibrinolytics or

thrombolytics, or through minimally invasive surgical approaches such as coronary
angioplasty.5 In the case of damage to the coronary arteries, blood flow may be restored
through bypass surgery.6 These treatments are effective in improving the initial patient
survival after infarction; however, they fail to address the long-term biological and
structural changes that occur with MI. Ultimately, many patients with an MI proceed to
develop heart failure in the long-term, with nearly a 50% mortality rate at 5 years after
hospitalization.1
Managing heart failure currently involves pharmacologic interventions to increase
blood flow to the myocardium and to reduce stress on the heart by reducing heart rate
and blood pressure (beta blockers and ACE inhibitors).5 Currently, the only way to return
to stable, healthy cardiac function in those with end-stage heart failure is through
transplant, where donor hearts are very limited.7 Mechanical interventions such as left
ventricular assist devices (LVADs) provide a temporary solution to induce systemic
blood flow; however, LVADs are not currently seen as a permanent solution for patients
with heart failure.8,9 Collectively, while these treatments are effective in mitigating the
issues associated with heart failure after MI, they fail to directly address the underlying
biological processes involved early on in the progression of the disease.

1.2. DISEASE PROGRESSION AND LEFT VENTRICULAR REMODELING AFTER MI
The initial ischemic event that leads to MI is followed by a three-phase wound
healing response consisting of inflammatory, proliferative, and maturation phases
(Figure 1.2).10 During the inflammatory phase, monocytes infiltrate the infarct region and
differentiate into macrophages, which serve to phagocytose cellular debris, secrete a
variety of inflammatory proteins, and stimulate fibroblasts towards the secretion of
proteases, which degrade the local environment. These protease levels remain elevated,
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and along with a concurrent decrease in the endogenous inhibitors (tissue inhibitors of
metalloproteinases, TIMPs), contribute to an overall increase in proteolytic activity and a
general loss of integrity of the extracellular matrix in the infarcted myocardium.11-14
During the proliferative phase, fibroblasts begin to deposit fibrous tissue and in the
maturation phase, matrix crosslinking and further apoptosis of myofibroblasts leads to
the formation of a fibrous scar. Generally, the beginning of cardiomyocyte death and the
inflammatory phase commences within hours of the initial infarct, and can last for several
days to a week after infarction. The proliferation of myofibroblasts follows, as well as the
upregulation of protease activity and can last for several weeks. Finally, in the following
weeks to months after these phases, scar tissue matures.10 While these phases give a
general outline of the biological changes after MI, they are not necessarily sequential, as
things such as protease activity and cardiomyocyte death are progressive with time, and
often continue for months after an MI.
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Figure 1.2. Phases of wound healing after myocardial infarction and their
underlying biological processes. The initial ischemic event as part of myocardial
infarction is followed by three distinct phases with unique underlying biological
processes. During the inflammatory phase, cardiomyocytes undergo apoptosis and
necrosis, leading to an immediate loss of the functional cell type in the infarcted region.
This is followed by an invasion of neutrophils and monocytes that directly and indirectly
contribute to an elevation in MMP activity, phagocytosis, and general degradation of the
extracellular matrix. This phase is followed by a proliferative phase during which
fibroblasts differentiate into myofibroblasts and commence production of collagenous
matrix, while endothelial cells contribute to angiogenesis and the production of new
vessels. Finally, in the maturation phase, matrix is crosslinked into a dense collagenous
scar. Adapted from Matsui et al. 10
Concomitant with these biological changes, global changes occur in the left
ventricle (LV) known as left ventricular remodeling.15 During LV remodeling, the LV
transitions to a dilated state, which includes expansion of the initial infarct region and
thinning of the myocardial wall (Figure 1.3).12,15 These changes result in a loss of
pumping efficiency in the heart and ultimately contribute to the progression of long-term
heart failure and mortality.12,15,16
The elevation of matrix metalloproteinases (MMPs) and subsequent loss of
matrix mechanics has largely been implicated in LV remodeling.11-14,16-19 These
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proteinases are secreted by a variety of cells, including endogenous cardiac fibroblasts
and cardiomyocytes as well as invading cells mobilizing as part of the inflammatory
response. Of key importance after MI, are MMP-1, MMP-2, MMP-3, MMP-7, MMP-8,
MMP-9, and MMP-14, which have been shown to increase after MI.20 This activity often
persists long after the development of an infarction (Figure 1.4). Directly, this family of
proteins is responsible for degradation of highly specific peptide sequences in the ECM.
This proteolytic activity alters a number of downstream processes in the infarcted
myocardium, including tissue mechanics, inflammation, cell invasion, and even direct
feed-forward regulation of other subtypes of MMPs.20,21 Ultimately, elevation of MMPs
has been correlated with a loss of function in the myocardium.

Figure 1.3. Ventricular remodeling after acute MI. After initial infarction, the portion of
the myocardium affected by the infarct begins to expand during the initial hours to days.
Within days to months, there is global remodeling in the LV that leads to a decrease in
systolic function, ventricular dilation, and thinning of the myocardial wall, all of which
contribute to the progression of long term heart failure. Adapted from Jessup et al.23
In addition to the elevation of proteinases after MI, a subsequent down-regulation
of their endogenous inhibitors, TIMPs, also contributes to the net effect of this proteolytic
activity. Because of the disruption of this balance, experimental interventions restoring
MMP inhibitory action in the myocardium through the delivery of exogenous inhibitors
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have proven effective in improving functional outcomes.19,22 Indeed, it has even been
hypothesized that currently administered clinical therapeutics may have partial benefit
due to their influence on MMP activity and regulation in the myocardium.20

Figure 1.4. Relative activity of MMP subtypes and TIMP subtypes in various
regions of the myocardium. Analyzed at 8 weeks after infarction in an ovine model of
MI, researchers observed an elevation of MMP activity most strongly in the infarct region
in the MMP-2, MMP-8, MMP-13, and MT1-MMP subtypes. This was coupled with a
relative decrease in TIMP-1,-2, and -3 subtypes in the infarct region. Adapted from
Wilson et al.11
Ultimately, this collection of maladaptive changes presents a number of crucial
barriers that prohibit the healing of the myocardium and a return to the pre-MI healthy
tissue state. First, an acute loss of matrix integrity contributes to infarct expansion and
global LV remodeling. Furthermore, necrosis of cardiomyocytes provides an irreversible
loss in contractility, as these cells have little innate regenerative capacity. Finally, in the
long term, the infarcted tissue transitions to a collagen-dense non-contractile tissue with
little vascularization. Despite these challenges, understanding of the remodeling
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processes can help guide new patient therapies.

For example, blocking of early

increases in MMP activity to salvage matrix mechanics or regenerative approaches
revascularizing or inducing cardiomyocyte proliferation in the infarct may improve clinical
outcomes. Often, these approaches require localization to the myocardium, and are
facilitated through the use of biomaterials.

1.3. HYDROGELS IN CARDIAC REMODELING
Biomaterials have recently become a strategy to address the barriers to recovery
that are faced after an infarction.24 Initially, mechanical restriction of the left ventricle
using epicardial wraps was shown to be effective in attenuating LV dilation and infarct
expansion.25-27 These studies were followed by the use of commercially available dermal
fillers as direct injections into the myocardial wall, which were also successful in
attenuating LV remodeling and promoting improved functional outcomes.28
In addition to polymeric meshes, hydrogels have also been used as therapies to
the heart after MI. Hydrogels are water-swollen polymer networks that can be made from
synthetic or natural polymers, and are cross-linked in either covalent or non-covalent
manners. Early work investigating the utility of hydrogels in the myocardium began with
Christman et al and the use of fibrin glues.29 This field has evolved and numerous types
of hydrogels have now been investigated after MI.24 Synthetic materials such as
pNIPAAM and PEG have been explored, as well as a wide range of natural materials
including alginate, collagen, chitosan, hyaluronic acid, as well as extracellular matrix
products.30-38 These materials have been crosslinked utilizing a variety of mechanisms,
including

covalent

mechanisms,

thermo-responsive

gelation,

ionic

crosslinking,

enzymatic crosslinking, as well as self-assembly. Hydrogels are most commonly
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delivered directly into the myocardial wall, which has been done through direct epicardial
intramuscular injections, as well as intra-coronary and endocardial approaches.
Recently, these approaches have resulted in the formation of several products in
early phase clinical trials. VentriGel, a product of Ventrix, is a porcine ECM product that
is delivered via an endocardial catheter based approach and is in Phase 1 clinical trials
(NCT02305602). Algisyl, a product of LoneStar Heart Inc., is an alginate product that is
directly injected into the myocardium. Algisyl has shown efficacy in improving aerobic
capacity of patients presenting heart failure, where hydrogel injections are applied
concurrently with other standard treatment procedures such as valve replacement or
bypass grafts.39,40 In short, hydrogels have developed into a robust tool to address LV
remodeling that is beginning to see clinical translation.
Mechanistically, these pre-clinical and clinical hydrogels are thought to impact
remodeling by altering the mechanical forces experienced by the heart through bulking
the myocardial wall.24 The law of Laplace states that the wall stress experienced by the
LV is inversely proportional to the thickness of the myocardial wall. By increasing the
wall thickness with hydrogel injections, wall stress can be reduced (Figure 1.5). Both
modeling and empirical approaches have shown the effect of alterations in injection
volume and material mechanics on the mechanical forces acting on the myocardium.37,41
While it is likely that the functional improvements observed are a result of direct
mechanical alterations in the myocardium, a number of biological pathways persist that
are not targeted by hydrogel mechanics alone. For example, biomaterials through their
innate or designed inflammatory response may lead to alterations in local collagen
production that can act to stabilize the tissue.
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Figure 1.5. Finite element model of hydrogel injection into the myocardial wall.
Nine injection sites of 150 µL hydrogel volumes at 0.1 kPa (a), 25 kPa (b), and 100 kPa
(c) or using 300 µL volumes at 0.1 kPa (d), 25 kPa (e), and 100 kPa (f). Myocardial wall
stress (represented by the colorimetric scale) is reduced proportionally to hydrogel
stiffness and volume of injection. Adapted from Wang et al. 41
In addition to providing mechanical intervention, hydrogels have the capacity to
provide numerous other therapeutic strategies in MI. As lack of innate cellular
regeneration is a significant barrier to restoration of normal function in the myocardium,
cellular delivery is one approach to improving cardiac function. Numerous clinical trials
have been investigated on the delivery of a variety of cell types (bone marrow derived
stem cells, mesenchymal stem cells, endothelial progenitor cells, and cardiac stem cells)
to the myocardium.42 Clinical efficacy of these trials has been mixed and have largely
been dependent on both cell lineage, viability, and retention in the myocardium.
As direct injections of cells alone often result in significant cell death, hydrogels
have been designed as carriers for a variety of cell types to optimize cell viability,
retention, and cell-material interactions at the injection site.29,43,44 While these strategies
have been effective, it is often difficult to pinpoint mechanistically the effect of cell
delivery as their interactions are often complex. Additionally, logistical concerns of cell
source and quality are often a concern when translating these therapies.
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1.4. HYDROGELS FOR DRUG DELIVERY IN THE MYOCARDIUM
Towards more controlled biological interventions, hydrogels have also been used
as drug delivery vehicles for a wide variety of payloads. From a design perspective,
hydrogels have numerous features that can be tailored to influence drug release across
a range of size scales (Figure 1.6). At the largest scale, hydrogel size can influence
drug release, as smaller sizes and increasing surface area contact with the environment
will lead to more rapid release.45 At the meso scale, hydrogels can be designed as either
non-porous materials or to be macroporous, with an increasing porosity often associated
with more rapid drug release.45

Figure 1.6. Overview of hydrogel design parameters influencing drug release.
Hydrogel size, porosity, mesh-size, and chemical linkers all contribute to the controlled
release of encapsulate payloads. Adapted from Li et al. 45
At the micro- and nano-scales, hydrogel mesh size is also a key influencer of
drug release properties. This property may be influenced through a variety of factors
including polymer concentration, crosslinking density, and crosslinker degradability
(Figure 1.7).45 This mesh size can be largely static, or increase through hydrogel
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swelling and degradation (Figure 1.7). Furthermore, the relative relationship of mesh
size to drug size also contributes to release behavior of drugs from hydrogels, with
meshes much larger than the drug providing rapid diffusive mediated release of drug
molecules and meshes on the same or smaller size scale than drugs being mediated
primarily through degradation or slow diffusive release.45 Because of this, as a handle for
tuning drug release, hydrogel mesh size is often restricted for utilization with large
molecules such as proteins or plasmids.

Figure 1.7. Influence of mesh size on encapsulated drug release from hydrogels.
Hydrogel mesh size influences drug release by exerting an effect on diffusive,
degradation, or swelling mediated drug release. The degree to which hydrogel mesh
influences drug retention/release is largely dependant on the relative size scales of the
mesh size and drug payload. Adapted from Li et al.45
Finally, drug release may be influenced at the nano scale through control of
payload interactions with the hydrogel. Covalent conjugation strategies may be utilized
to directly immobilize therapeutics on the hydrogel, with linkages being designed to be
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stable or cleavable under a variety of conditions (Figure 1.8).46 Furthermore, noncovalent interactions, such as electrostatic or hydrophobic interactions may also be used
to introduce an affinity of therapeutics to the hydrogel, and subsequent slower release
properties.45 While these strategies may be used for large molecule therapeutics, they
are almost exclusively used to manipulate the release of small molecules from hydrogel
materials.

Figure 1.8. Chemical interactions between payload and hydrogel may influence
drug release properties. Designing chemical interactions into the hydrogel provides
another mechanism for controlling drug release properties. This may be achieved
through covalent conjugation of drugs to the hydrogel, or by designing electrostatic or
hydrophobic interaction into the hydrogel material to provide affinity to the hydrogel for
the payload molecule.
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A variety of protein-based payloads have been delivered to the heart, targeting a
number of biological steps after MI.47 In one approach, hydrogels were used to deliver
anti-apoptotic molecules in order to attenuate cell death following MI.48 In one study,
Ruvinov et al. developed alginate microspheres encapsulating insulin-like growth factor
1 (IGF-1) and hepatocyte growth factor (HGF).48 IGF-1 is a cytoprotective factor while
HGF has angiogenic and anti-fibrotic properties. These microspheres were administered
to the infarct to provide a sustained release of both drugs, with the hypothesis that there
would be a cumulative effect from both factors. Injection of these microspheres after MI
showed improvements in key markers such as reduction in fibrotic area, improvement in
apoptotic cells, increased vessel densities and proliferation of cardiomyocytes at 4
weeks after injection, as compared to factors injected in saline and blank microspheres.
IGF-1 has also been used in other classes of hydrogels, such as a selfassembling peptide based hydrogel designed by Davis et al.49 This material utilized
streptavidin-biotin binding to provide long-term release of IGF-1 (84 days) and showed
significant functional benefits when the hydrogels were utilized to co-deliver IGF-1 and
neonatal cardiomyocytes. IGF has also been delivered using a PEG-based selfassembling block copolymer system that can be administered using catheter-based
approaches. This material has shown efficacy in improving functional outcomes such as
ejection fraction, as well as improvement in tissue-level outcomes such as the formation
of new cardiomyocytes, and increased vascularization.50
In addition to targeting cytoprotection, hydrogels have been widely used for the
delivery of angiogenic proteins, as a means to promote neovascular formation in the
ischemic myocardium. One factor, fibroblast growth factor (FGF) has been used as a
payload in a variety of hydrogel systems51-56. While FGF is a potent stimulator of
angiogenesis, it suffers from a very short half-life in-vivo. As a means to address this
limitation, Sakakibara et al utilized gelatin hydrogel microspheres as a delivery vehicle
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for FGF, and showed through radiolabeling studies that effective doses of FGF could be
sustained in the myocardium.52 Furthermore, this corresponded to improvements in LV
remodeling and neovasculature formation at 4 weeks after MI. This growth factor has
also been delivered from a variety of other hydrogels, including thermoresponsive
chitosan hydrogels.51
Vascular endothelial growth factor (VEGF), a stimulator of proliferation and
migration in endothelial cells, has frequently been delivered to stimulate the growth of
new vessels. While this is a key component in angiogenesis, often vessels require the
recruitment and proliferation of smooth muscle cells to provide appropriate maturation.
This dual delivery approach has been conducted using simple alginate hydrogels, as
well as coacervates to provide for further control of release timing for each of these
molecules.57,58 These approaches have shown success in the generation of αSMA
positive vessels over either growth factor individually, as well as benefits to cardiac
function. In addition to delivering these factors as freely soluble components, other
groups have immobilized angiogenic factors on hydrogel surfaces to provide a sustained
effect after injection. For example, Wu et al. immobilized VEGF to PEG block
copolymers using NHS chemistry.59 These VEGF modified block copolymers were
thermoresponsive, to provide a gelation mechanism after injection into the myocardium.
Results from this study showed improved cardiac function and tissue morphology (scar
fraction, capillary density) in hydrogels modified with VEGF as opposed to unmodified
hydrogels, suggesting that immobilized proteins are also an effective strategy for
inducing biological responses in the myocardium.
Other recent strategies focus on delivering therapeutics that manipulate cell
recruitment and cell proliferation in the myocardium. In one strategy, stromal derived
factor-1 alpha (SDF-1α) was utilized for its ability to recruit progenitor cells. SDF-1α has
been delivered via covalent immobilization to self-assembling peptide hydrogels, as well
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as encapsulation in hyaluronic acid hydrogels.60-62 These strategies have shown
structural benefits, including an increase in progenitor cells possessing the receptor for
SDF and a concomitant increase in capillary density, as well as benefits in cardiac
function. Furthermore, other SDF analogs have been delivered in order to improve the
stability of the chemokine signal, as SDF is susceptible to protease degradation.61 Other
strategies focus on directly improving proliferation of non-proliferative cardiomyocytes.
Mir-302, a micro RNA influencing transcription along the Hippo pathway, was delivered
using an injectable hyaluronic acid hydrogel.63 Utilizing a confetti mouse model, the
study showed the ability for this payload to stimulate clonal expansion of
cardiomyocytes, which contributed to overall improvements in cardiac function.
One final strategy that hydrogels have employed for drug delivery is the delivery
of inhibitors for MMPs. Proteases are maladaptively upregulated in the infarct tissue, and
inhibition of this activity has lead to improved outcomes through the use of systemically
administered protease inhibitors.22,64-67 Local delivery with hydrogels, however,
attenuates off-target effects of these inhibitors on normal matrix turnover, which is
important to mitigating harmful side effects of these molecules during systemic
administration. TIMPs are protein-based inhibitors that the body uses to regulate MMP
activity. As a strategy for local MMP inhibition, TIMP-3 has been delivered locally from
injectable hydrogels in pig studies.68 As a means to provide different mechanisms of
control, TIMP-3 was delivered passively using covalently crosslinked hydrogels, or in
response to protease degradation in protease cleavable hydrogels.68,69 These systems
showed the benefit of TIMP-3 payload in hydrogels on local MMP activity as well as
ventricular geometry and function. This strategy has also been employed utilizing
peptide-based inhibitors delivered using a thermogelling system based on NIPAAM,
which showed an ability to decrease MMP activity and improvements in ventricular
structure and function. 70
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1.5 CONCLUSIONS
MI is a widely prevalent condition that leads to an array of progressive changes
in the heart, which ultimately may contribute to long-term heart failure. Current treatment
methods fail to address the underlying biological changes that occur after an infarction at
the acute time points, driving a need for improved therapies. As a result, injectable
hydrogels have developed into a burgeoning field of cardiac intervention, providing
mechanical support in the left ventricle after MI. These materials have subsequently
been used to further address the underlying biology as drug delivery vehicles, delivering
a variety of payloads locally that can attenuate cell death, promote cell recruitment and
proliferation, generate new vasculature, or provide inhibition of MMPs.
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CHAPTER 2
RESEARCH OVERVIEW
2.1 SPECIFIC AIMS
It is clear that biomaterials are emerging to have an important role in the
treatment of various cardiac diseases and conditions.1-7 Specifically, hydrogels (waterswollen polymer networks) are being developed to treat patients after myocardial
infarction (MI), due to their tunable properties and potential for percutaneous delivery to
the heart.6 Hydrogels are comprised of either natural or synthetic polymers and can be
used to influence mechanical properties in the myocardium or as a delivery vehicle to
improve the retention and viability of cells or the sustained delivery of therapeutics.6,8-10
Self-assembled hydrogels, formed using reversible, non-covalent bonds as
crosslinks, are one class of hydrogels that possess a number of unique properties that
make them highly amenable for clinical translation in myocardial applications.11
Specifically, these materials are shear-thinning and self-healing, allowing them to be
easily injected.12,13 This is often advantageous when compared to traditional covalent
systems that suffer from issues associated with reaction times that can lead to difficulty
in handling by clinicians (e.g., clogging of delivery devices), as well as the potential for
extravasation when injected into tissue.11 In comparison, shear-thinning allows for
injection through a variety of syringes and catheters, while self-healing allows hydrogels
to re-form when they reach the desired tissue site.
Our lab has recently developed a two-component hydrogel system based on
hyaluronic acid (HA) that has been engineered for injection into the myocardium.4,13 HA
is a highly useful polymer for hydrogel design, as it is a naturally occurring component of
the extracellular matrix and is easily amenable to orthogonal chemical modification.14
This developed hydrogel is crosslinked through the directed self-assembly or guest-host

26	
  

(GH) chemistry between the hydrophobic cavity of β-cyclodextrin (CD) and the
hydrophobic small molecule adamantane (Ad). Simply, HA is modified with either CD or
Ad (CD-HA, Ad-HA) and gelation occurs when the two solutions of CD-HA and Ad-HA
are mixed, to form a hydrogel with shear-thinning and self-healing behavior.13
Although this general hydrogel system has been explored previously to alter
myocardial mechanics and for the delivery of several molecules (e.g., microRNA,
extracellular vesicles), there is still much work to expand the hydrogel to the widespread
therapeutics that are of interest to treat patients after MI.

4,5,15,16

To address this, the

overarching objective of this thesis is to advance GH assembled materials for the
delivery of small molecule therapeutics, as well as to design new GH assembled
materials with complex multifunctional properties. The following aims serve to guide this
objective, investigating material structure and properties that govern their therapeutic
efficacy in influencing the remodeling myocardium after an infarction.

Aim 1: Design an easily injectable guest-host hydrogel formulation for sustained
small molecule delivery
Hypothesis: The host molecule (CD) within GH hydrogels will bind to encapsulated small
molecules to sustain and control their release behavior from hydrogels.

Hydrogels are often unable to serve as a delivery platform for small molecules,
as their large mesh sizes lead to the rapid diffusion of small molecules.17 Specifically,
hydrogels are inherently highly swollen in nature, providing minimal diffusive barriers for
encapsulated small molecule drugs, as their molecular mesh size is often much greater
than the entrapped molecule. This rapid diffusion limits the sustained release potential
for small molecule drugs from hydrogels. CD, with its cyclic structure and hydrophobic
core, is known to bind to many small hydrophobic molecules and has been used
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frequently as an excipient in the pharmaceutical industry to improve solubility and
absorption of hydrophobic small molecules.18,19 Given this broad affinity for small
molecules, we design hydrogels through GH assembly, leveraging CD for both hydrogel
formation and to retain small molecules within hydrogels. Molecule binding, diffusivity,
and release when encapsulated are explored as a function of hydrogel composition
(e.g., ratio of Ad:CD, polymer concentration). These studies expand our knowledge of
drug binding to sustain release from hydrogels and point to specific formulations that
may be investigated for treating MI.

Aim 2: Release a small molecule protease inhibitor from an injectable GH hydrogel
for treatment of MI
Hypothesis: A small molecule protease inhibitor SD-7300 can be released in a sustained
manner from GH hydrogels to improve functional and biological outcomes after MI when
compared to hydrogels alone or saline treatment.

Spatial inhibition of MMPs throughout the body, targeting of MMP subtypes, and
timing of MMP inhibition have been shown to play key roles in therapeutic benefit of
targeting MMP activity for therapeutics.20-25 This paradigm has translated to the
development of numerous small molecule inhibitors; however, off-target effects related
to the systemic delivery of broad-spectrum MMP knockdown has limited their translation.
For example, SD-7300, an MMP-1 sparing small molecule inhibitor (Pfizer), has shown
pre-clinical potential as an MI therapeutic, but only with off-target effects. Thus, the local
delivery of SD-7300 may overcome these limitations. To address this, we develop a
specific injectable GH hydrogel formulation, where interactions with CD lead to sustained
release.

Further, a large animal model of ischemia-reperfusion in swine is used to

demonstrate the ability of the injectable hydrogel delivering SD-7300 to alter remodeling
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outcomes and improve functional outcomes.

These studies provide an innovative

approach for targeted, localized MMP inhibition in the infarcted myocardium with broad
impacts on evolving strategies for pharmaceutical MMP inhibitor therapies.

Aim 3: Develop an injectable granular hydrogel system for treatment of MI
Hypothesis: Shear-thinning hydrogels can be assembled through the GH interactions of
polymers and microgel components with properties of degradation, molecule release,
and cell invasion based on microgel design.

Towards designing material systems for application in the myocardium, it is
important to consider multifunctional behavior including drug release, cell invasion, and
microstructure. These properties are difficult to integrate into a single injectable material,
limiting the scope of biomaterial-based approaches in MI interventions. Emerging
classes of materials with potential to design modular, multi-therapeutic release systems
include granular hydrogels, where microgels are assembled into a bulk hydrogel.

26-28

As

GH chemistry provides a directed and highly controllable mechanism of self-assembly,
we engineer unique materials based on the assembly of covalently-crosslinked
microgels modified with Ad with CD-HA polymers. We investigate the rheological
properties of these materials, as well as the degradation and release behavior of
granular hydrogels assembled through microgels crosslinked with either stable or
protease-degradable crosslinks. Further, these materials are investigated after injection
into a rat model of MI, where features such as microgel erosion and the ability to alter
remodeling outcomes are investigated. Thus, this aim designs innovative, multi-scale
materials using the self-assembly of microgel components to provide multi-functional
benefit in the infarcted myocardium.
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2.2 CHAPTER OUTLINE
Chapter 1 provides an in depth overview of MI and a summary of the biological
mechanisms behind left ventricular remodeling.

Further, the various hydrogel

approaches and specific systems that have been pursued for treating MI, including
through mechanical intervention, cell delivery, and drug delivery are summarized.
Chapter 3 shows a more focused review of GH assembled biomaterials, including the
various GH pairs that have been explored in the development of biomaterials and their
role in drug delivery and other therapeutic applications.
Chapter 4 describes the scientific research proposed in Aim 1, outlining the
tunable parameters in GH hydrogels for the sustained release of a variety of therapeutic
small molecules payloads. Chapter 5 describes the scientific research proposed in Aim
2, outlining the development of a GH formulation suitable for the delivery of SD-7300
and its application in a porcine model for MI. Chapter 6 describes the scientific research
proposed in Aim 3, outlining the development of a multifunctional granular hydrogel and
its application in a rat model for MI.
Finally, Chapter 7 provides a summary of the work presented, illuminating the overall
impact of GH hydrogel systems for the delivery of therapeutics after MI. Limitations of
these material systems are discussed, and potential future directions are proposed that
may further expand the application of these hydrogels.
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CHAPTER 3
SUPRAMOLECULAR GUEST-HOST INTERACTIONS FOR THE PREPARATION OF
BIOMEDICAL MATERIALS

Adapted from:
Rodell CB, Mealy JE, Burdick JA. Supramolecular guest–host interactions for the
preparation of biomedical materials. Bioconjugate chemistry. 2015 Oct 16;26(12):227989.

3.1. INTRODUCTION
While chemists have traditionally focused on methods of assembling atoms and
molecules through the formation and rearrangement of covalent bonds, it has been
elegantly noted that this strategy pales in comparison to the array of possible
interactions utilized in nature to develop large, complex molecular structures through
non-covalent bonds.1 These interactions are encompassed within the field of
supramolecular chemistry, which includes electrostatics, hydrogen bonding, van der
Waals forces, п-п interactions, and hydrophobic or hydrophilic attraction for molecular
assembly.2 While such interactions have long been known, the field has continued to
rapidly expand since the 1987 Nobel Prize was awarded to Pedersen,3 Cram,4 and
Lehn5 for their pioneering work in formalizing synthetic methods in this area.
Lehn described the concept of supramolecular assembly as “chemistry beyond
the molecule.”

5

This is because the non-covalent nature of supramolecular bonds

renders them inherently weaker than covalent bonds and they may therefore exhibit
thermodynamic or forcefully induced rearrangement. As a result, supramolecular bonds
display a capacity for directed assembly at length scales far exceeding that of single
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atoms or molecules, such as with the formation of higher order structures in biological
proteins and tissues. The capacity for spontaneous and reversible binding between
molecular species is likewise a driving force in the development of structured,6-8
dynamic,9 and self-healing10 materials, as well as in pharmaceutical applications11-13 and
directed cell-material interactions which will be discussed herein.
One

particular

subset

of

supramolecular

chemistry,

namely

guest-host

interactions, is of particular interest toward the biomedical community. These bonds are
based on the transient association of a molecule containing a cavity (i.e. a cavitand) with
suitable molecular guests. The family of cavitands includes both naturally-derived (e.g.
cyclodextrin) and synthetic (e.g. cucurbit[n]urils, calix[n]arenes, and pillar[n]arenes)
macrocycles.12,14-16 The criteria for a guest-host pair involves complementary size of the
host cavity and guest molecule, as well as their specific interactions (predominantly
through hydrophobic attraction).17,18 These broad criteria lend themselves to the pairing
of macrocycles with numerous potential guests, which may be inert or stimuli-responsive
molecules, pharmaceuticals, biomolecules (i.e. peptides, proteins), polymers, or other
chemical species. Owing to the array of guest and host molecules and their synthetic
flexibility, incorporation of these groups into polymeric materials may be easily achieved
for a diverse range of biomedical applications. Despite recent developments in polymeric
guest-host materials, there remains a tremendous capacity for growth in the biomaterial
utilization of these unique chemistries. Toward elucidating these future directions, this
review will highlight recent advances in both our understanding and application of
materials and interactions mediated by guest-host macrocycle assembly.

3.2. MECHANISMS OF SELF-ASSEMBLY
3.2.1. DIRECT MOLECULAR RECOGNITION
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Supramolecular assembly may be ambiguous, with non-specific interactions
between numerous groups. Examples of such interactions in material assembly include
the formation of hydrophobic crystalline domains or charge-based assembly of
polyelectrolyte or polyampholyte polymers. These interactions may be preferable in
some cases, such as to facilitate incorporation of hydrophobic19,20 or charged drugs21,22.
However, such assembly processes involve development of long-range order over
relatively long timescales, which may hamper rapid formation and recovery. Moreover,
the prevalence of competitive binding groups (i.e. any non-charged molecule, salts) may
disrupt bond formation and material assembly. Thus, it is important to define
supramolecular interactions that have more specific associations to fabricate robust
materials for biomedical interactions.
Toward this, direct associating systems are based on specific molecular
recognition of a guest by its corresponding host molecule upon mixing (Figure 3.1).
Such direct interactions do not require long-range order and therefore occur rapidly, with
timescales governed by the association constant (ka), enabling rapid initial material
formation and self-healing upon rupture. Numerous molecular structures have been
identified and designed to form guest-host pairs. These include the relatively weak
association of crown ethers, cryptands, and related molecules;23,24 though, such
associations are generally more suited for ionic sequestration and not molecular
recognition. Alternatively, an array of transient peptide and/or protein interactions have
been devised,25-29 which often display greater affinity and specificity, but at the cost of
increasing complexity and laborious synthesis. Finally, the guest-host macrocycles
combine rapid, high affinity molecular recognition with ease and scalability of synthesis.
Of the guest macrocycles, cyclodextrin (CD) is the most prevalent due to its
relatively high water solubility, low toxicity, and extensive history of use. The first
reference to CD was that of Villiers, in 1891, who isolated a crystalline substance
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following bacterial digestion of cellulose.30 While research continued on the formation
and characterization of these crystalline dextrans, nearly half a century passed before
their cyclic structure was proposed (D-glucose units arranged in a toroidal fashion
through α-1,4 glycosidic bonds) and isolation of homogenous fractions of α, β, and γ
cyclodextrin (which contain 6, 7, or 8 repeat units, respectively) was accomplished.14
Importantly, improvements toward these synthesis and purification processes have
proceeded to industrial scale, as have many strategies for their synthetic modification,
resulting in a relatively cheap and abundant material source.14,31 Enabled by the
scalability of synthesis, CD molecules are used in a variety of industrial, commercial, and
pharmaceutical applications and have been categorized by the Food and Drug
Administration as “generally recognized as safe” (GRAS).32-34 Moreover, the cavity sizes
of CDs allow them to include a range of guest hydrophobic molecules in its interior. Of
these potential guest molecules, adamantane (Ad) is widely regarded as having one of
the greatest affinities (Keq ≈ 105 M-1) due to its complementary size for βCD and high
hydrophobicity.35 Alternatively, responsive guest-host interactions have emerged as a
means of regulating these intramolecular interactions. These include azobenzene and
ferrocene, which are known to interact with numerous species of CD and are responsive
to light36 and redox conditions,37,38 respectively. This behavior renders them particularly
useful toward the development of responsive delivery vehicles,39 actuating materials,40,41
and dynamically assembling systems.42-44
More recently, alternate cavitands have emerged and demonstrated relevance
toward biomedical applications. This second generation of cavitands includes
cucurbit[n]urils (CBs), pillar[n]arenes, and calix[n]arenes. While CBs were first prepared
in 1905,45 investigation of their structure was not performed until 1981,46 and numerous
CBs (typically 5-10 repeat units) have since been explored. Recent examination has
revealed mild in vitro toxicity of these groups, though only at doses far exceeding those
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typical in vivo, supporting their continued pharmaceutical use.47 Binding affinities for CBs
are often greater than that of other cavitands and can reach values as high as Keq ≈ 1015
M-1.48 This may be attributed, in part, to the binding of guest molecules through a
combination of hydrophobic and cation-dipole interactions.48-50 Moreover, the unique
geometry of CB[8]s allows for multivalent binding of guest molecules (such as
naphthalene and methyl viologen), which enables reinforcement of binding affinity by
cooperation between п-п stacking or charge-transfer interactions for guest-host complex
formation.51 Recently, the use of the cup-shaped calix[n]arenes and pillar-shaped
pillar[n]arenes toward biomedical applications has begun.12 Their translation to this field
has been previously hampered both by lower guest-host affinity and water solubility
when compared to their CD and CB counterparts; though, recent work has sought to
improve the affinity and water solubility of these macrocycles such as through repeated
and efficient modification with solubilizing functional groups,52 resulting in macrocycles
with improved utility in aqueous environments.

Figure 3.1. Molecular guest-host assembly. (A) Generalized schematic of host (red)
interaction with its corresponding guest (blue) to form a guest-host complex (purple),
with bonding equilibrium governed by the association (ka) and dissociation (kd)
constants. (B) Schematic representation of cavitand host species, represented by
pillar[5]arene, calix[4]arene, cyclodextrin, and cucurbit[n]uril.
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3.2.2. POLYMERIC ASSEMBLY
Guest-host molecular recognition is particularly useful for the formation of
supramolecular structures (i.e. guest-host hydrogels). Toward hydrogel formation,
pioneering work by Harada demonstrated that poly(ethylene oxide) (PEO) could be
threaded within multiple αCD moieties, yielding a rotaxane structure.53 Pursuit of such
systems further illustrated the formation of pseudopolyrotaxanes and a sol-gel transition
upon simple mixing of PEO and αCD through crystallization of CD domains (Figure
3.2A).54 These and similarly formed pseudopolyrotaxanes, such as through pendant
polymer modification with PEO or similar polymers (Figure 3.2B), have since become a
basis for supramolecular assembled hydrogels which have been separately reviewed.55
Such systems may be limited in therapeutic use, due to long recovery times after
injection,56 which may hinder injection site retention, and the inaccessibility of CD in the
network to interact with surrounding molecules.
Alternatively, modification of polymers with guest and host groups (either as endgroups or pendant modification) has become the primary method for fabrication of
supramolecular networks from guest-host interactions. For example, the endmodification of mono- and bifunctional polymers has been examined (Figure 3.2C),	
  
where potential applications may include the self-sorting of linear supramolecular
polymers or assembly of block copolymers with utility toward such materials as
responsive micelle assembly.57-59 In extension of this methodology, multiarm PEO has
been modified with either βCD or cholesterol (the guest molecule) and van de Manakker
and colleagues demonstrated formation of supramolecular hydrogels by mixing these
precursors with controllable rheological erosion, and cargo release profiles.

60,61

Similarly, Charlot et al. extensively explored the rheological behavior of binary
associating systems by conjugating βCD and Ad to chitosan, hyaluronic acid (HA), and
other polymers as pendant groups (Figure 3.2D). While low modification resulted in
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weak supramolecular networks (typical G’ < 100Pa), their results demonstrated the
importance of polymer concentration, charge, and competitive binding on network
assembly.62 Moreover, theoretical and experimental approaches have been combined to
illustrate the importance of multivalent and inter-polymer interaction to generate high
avidity and network stability.63,64 Toward harnessing this understanding, our group has
demonstrated that higher degrees of modification of HA with these same guest-host
groups enables formation of more robust supramolecular hydrogels (G’ = 10 kPa
possible) through generation of larger net avidity between polymers which may be
enhanced by multifold polymer junctions.65
CB macrocycles have also been explored to produce robust supramolecular
hydrogels. This work has been pioneered by the Scherman group, where polymers were
modified with pendant methyl viologen or napthoxy derivatives that form ternary
complexes with soluble CB[8] with high affinity (Ka ≥ 1011 M-2, Figure 3.2E). Such
materials resulted in good network mechanical properties (typical G’ > 500Pa) even at
low polymer modification (5-10% of repeats).66,67 For further information regarding
polymer architecture and molecular organization in guest-host hydrogels and their
influence on bulk hydrogel properties, the reader is referred to extensive reviews that
cover these topics.2,68
Beyond the ability to assemble into networks, supramolecular guest-host
interactions may be used to introduce structure at the nano- and micro-scales. Indeed,
the organization of many natural structures is driven by supramolecular interactions,
such as native extracellular matrix (e.g., fibrillar structure of collagen) and the DNA
superstructure. Such aspects may be recapitulated by synthetic analogues.69,70
Observations of such behavior have been noted in numerous self-assembling systems
including peptide amphiphiles71, DNA-based hydrogels72, dendritic materials8, and PEGbased supramolecular systems73. In recent years, there have been numerous reports
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indicating that similar hierarchical structures are possible in guest-host hydrogels,
though most include only observation of dried samples by electron microscopy. Recent
reports have shown the formation of nanoparticles with well controlled size through
synthesis of diblock copolymers containing βCD.74 Moving this structure into twodimensional assembly, semi-rigid four-arm macromolecules have been modified by
methyl viologen and 2,6-dihydroxynaphthalene which assemble into two-dimensional
films upon mixing with CB[8] in water. Both TEM and AFM confirmed a nanofibrillar
structure, and SAXS estimated the spacing of these features to be well approximated by
the theoretical pore size.75 In an interesting example of three-dimensional structure,
aggregation of N-isopropylacrylamide (NIPAAM) thermogels has been controlled by
introducing CB[7] as polypseudorotaxane side chains. Such inclusion results in semirigid polymer segments that induce transition from a globular to porous morphology that
could be observed by optical microscopy in a hydrated state.76 Control of physical
structure on these length scales holds great promise for the cell biology and biomaterials
fields, as dynamic self-assembly of these structures may best recapitulate the natural
processes that drive cell behavior. Though, systematic studies including the effects of
polymer architecture, bond affinity, and other variables are still lacking.
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Figure 3.2. Schematic representation of guest-host polymeric assemblies. (A, B)
CD-PEO pseudopolyrotaxanes; (C) supramolecular polymers from heterobifunctional (i),
homobifunctional (ii), and monobifunctional (iii) gelators;
(D) separate, pendant
modification by βCD and adamantane; and (E) separate, pendant modification of
polymers by methyl viologen or napthoxy derivatives with crosslinking by ternary
complexes with soluble CB[8].

3.3. DIVERSE BIOMEDICAL APPLICATIONS
3.3.1. INJECTABLE HYDROGELS
Injectable materials have become important in the biomaterials community as
they can be introduced in a minimally invasive manner through direct injection into a
tissue or via catheters. Many methodologies exist for formation of injectable materials,
including in situ gelling via initiated or autonomous polymerization, addition crosslinking,
or thermogelation; however, there are numerous limitations to such systems based on
gelation kinetics (i.e. too fast leads to clogging of delivery device, too slow leads to
material dispersion upon injection). Alternatively, guest-host hydrogels may be formed
prior to injection (Figure 3.3A, i) and extruded via shear-induced flow. Such shearthinning properties are of interest for numerous supramolecular hydrogels,77 due to their
dynamic bonds that can be broken and then reformed. Many practical requirements
should be considered when designing guest-host hydrogels as deliverable materials,
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such as the injection process (i.e., ease of injection and capacity for retention), as well
as the subsequent physical properties after injection (i.e., suitable moduli and
degradation times).
For shear-thinning materials, the injection process is governed by the material
response to shear stress; ideally, the material is pre-formed and then exhibits a
decrease in viscosity (i.e., shear-thinning) during injection that permits flow. Indeed, this
is the case for the majority of supramolecular materials, as the physical bonds that
permit assembly are temporarily broken (Figure 3.3A, ii). The kinetics of bond
formation, though, are of key interest to the shear response of hydrogels. Craig and
coworkers extensively studied the relationship of bond kinetics and polymer relaxation
timescales, demonstrating that disadvantageous shear-thickening behavior arises if
polymer relaxation occurs more rapidly than reconnection of broken crosslinks.78,79 As
such, the decreased polymer relaxation may be accomplished through formation of
multifold junctions in highly modified guest-host hydrogels to enforce shear-thinning
behavior and ease of injection.80 The physical chemistry underlying the flow process, as
well as other fundamental behaviors of supramolecular networks have been recently
reviewed.9 Beyond regulating flow properties, the binding kinetics are also essential
toward material formation following injection (Figure 3.3A, iii), as rapid bond reformation
is essential for material retention. In recent work, we demonstrated that rapidly selfhealing guest-host hydrogels are well retained (>98% of initial hydrogel volume) upon
injection into myocardial tissue, whereas slowly crosslinking covalent controls were not
retained as gelation was too slow.81 This high material retention is essential, including
toward successful implementation of injectable materials as tissue supplements, drug
reservoirs, or cell delivery vehicles as discussed in subsequent sections.
Also critical to the success of injected biomaterials are the final properties in vivo,
following injection. In many cases, material degradation may be desired to eliminate the
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need for implant removal or permanent implantation. Guest-host assembled materials
are of great utility toward this, as they undergo natural disassembly due to their dynamic
bonds (Figure 3.3A, iv). Thus, their rate of degradation can be controlled through
features such as material concentration, guest-host affinity, and number of guest-host
bonds.61,80 Additionally, the degradation rate of such materials may be altered by
inclusion of conventional degradation mechanisms, including hydrolysis or enzymatic
degradation. Toward such control of degradation, Tian et al utilized a hydrolytically
degradable poly(organophosphazine) backbone grafted with PEO of differing molecular
weights. In the presence of soluble αCD, hydrogels were formed which exhibited
controlled release of bovine serum albumin (BSA) over a period of 2-12 days, with
concurrent and prolonged hydrogel degradation.82 More recently, bioactive degradation
mechanisms have been demonstrated; in one embodiment, micelles and hydrogels were
formed through inclusion of glutathione in the micelle core to enable bioreduction of the
polymeric structures which controlled release of doxorubicin.83 Additionally, pendant Ad
modification of HA has included a peptide linker susceptible to cleavage by matrix
metalloproteinases (MMPs) that are naturally produced in remodeling of the extracellular
matrix. When combined with pendant modified βCD-HA, hydrogels were formed which
exhibited enhanced degradation in the presence of mammalian MMP-2.84 These means
of degradation are of interest to the biomedical community to ensure clearance of the
eroded materials (e.g. failed renal clearance of high molecular weight PEO may limit
applicability of αCD-PEO hydrogels without inclusion of such hydrolysis mechanisms)
and because bioresponsive degradation perpetuates such applications as on-demand
drug release and tissue-material integration.
As an alternative to enhanced degradation, prolonged material presence may be
desirable. Many supramolecularly assembled materials degrade in the course of days,
which may be too rapid for numerous applications in cell delivery or tissue repair. One

45	
  

approach to achieve improved degradation lifetimes is the use of higher affinity
interactions, such as CB[8] with an electron transfer pair, which has enabled sustained
release of biomolecules (BSA and lysozyme) for up to 160 days in vitro.85	
   Interaction of
CB[6] and polyamine modified HA has also been used, but implantation was achieved
not by shear-thinning injection but instead by sequential subcutaneous injection of the
two components, with supramolecular assembly in vivo. Inclusion of fluorescently
labeled CB[6] in the hydrogel demonstrated presence as long as 11 days, whereas the
free fluorophore was released within 24 hours as examined by in vivo fluorescence
imaging.86 These approaches demonstrate the capacity for high affinity guest-host pairs
to provide prolonged delivery of biomolecules by diffusion or through modular
modification with the host molecule, though such high affinity guest-host interactions
may limit shear-thinning properties, hindering their use as injectable materials.87
Alternatively, the use of secondary stabilization chemistries, subsequent to
supramolecular bonding, has been achieved to enhance mechanical stability without
affecting injectability. Such processes have been accomplished in protein-based
supramolecular assembly using photopolymerization or thermogelation as secondary
gelation mechanisms.28,88 To allow for in vivo crosslinking and long-term mechanical
stability, we have recently introduced secondary crosslinking in vivo through
autonomous Michael addition, enabling covalent crosslinking on clinically relevant
timescales. Application in a rodent model of myocardial infarct (MI) demonstrated a
capacity for mechanical stabilization of the injured tissue, tending to improve geometrical
and functional outcomes relative to untreated MI or guest-host material controls without
secondary crosslinking.81 Though, care should be taken in these approaches, as rapid
covalent crosslinking may result in delivery failure.
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Figure 3.3. Guest-host hydrogel injection. (A) Hydrogels are pre-formed within the
syringe through guest-host bonds (i) which are broken by shear stress (τ) within the
needle (ii). Following extrusion, bonds rapidly re-form (iii) to enable retention within the
tissue. Subsequent disassembly of the hydrogel in vivo occurs through spontaneous
dissociation of the dynamic bonds and resultant surface erosion of the polymer (iv). (B)
Representative oscillatory time sweep demonstrating initial hydrogel mechanics (i),
yielding to enable flow under high strain (ii), and rapid recovery (iii) such as that
proposed for injection. Adapted from Charlot et al. 63
3.3.2. THERAPEUTIC DELIVERY
In addition to formation of injectable materials by guest-host mediated selfassembly, these unique interactions have significant applications in drug delivery
strategies. The most widely used materials in this field have been the CD macrocycles,
as they have been used in many pharmacological drug formulations including
Sporanox©, Yaz©, and Abilify© among others.89 CDs form inclusion complexes with
various drugs, which improves the drug bioavailabilty by increasing drug solubility and
protecting

them

from

degradation,

which

has

been

reviewed

extensively

elsewhere.13,89,90 Guest-host interactions have also been used recently to develop
materials as drug delivery systems, providing novel biofunctionality through non-covalent
conjugation of bioactive pendant groups, as well as the development of bulk materials to
provide the controlled release of growth factors, genetic material, and small molecule
therapeutics.
While improving the physiochemical properties of drugs has prevailed in the
translational application of guest-host complexes, more advanced nanoparticle systems
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are also being developed. These systems leverage the formation of guest-host
complexes as a conjugation strategy to provide stealth or targeting, or to allow
nanoparticles to carry hydrophobic payloads (Figure 3.4A). Work from the Davis group
provides an excellent example of exploiting guest-host complexes in delivery systems
that have translated to clinical trials.91 They developed CD functionalized polymer
backbones that form polyplexes with siRNA payloads, with surfaces that may be
decorated with Ad coupled macromolecules such as PEG or transferrin.92-94 This type of
conjugation allows for rapid and modular modification of particle systems with a variety
of ligands. Similar non-covalent conjugation strategies have been employed using other
guest-host pairs such as CB[6] with polyamines to provide targeted delivery of
nanocapsules.95,96 In addition to strategies for noncovalent surface modification,
macrocycles have been incorporated into nanoparticles to act as molecular “docking”
sites that can facilitate drug loading (Figure 3.4B). This carrier functionality has been
exploited using amphiphilic CD nanocapsules to entrap tamoxifen, ionic βCD
nanoparticles as doxorubicin carriers, and CB[6] particles to carry paclitaxel.96-98
Furthermore, macrocycle interactions have provided an avenue for direct, noncovalent
conjugation of biofunctional groups to drug molecules (Figure 3.4C). As examples, βCD
functionalized with lactoferrin and saccharide ligands has been used to complex and
target drugs to lactoferrin and mannose receptors, respectively.99,100
In addition to nanoparticle strategies, guest-host systems have been leveraged in
bulk hydrogels to provide controlled release of therapeutic payloads. Many groups have
employed guest-host assembly to drive the formation of hydrogels that can provide
sustained release of biomolecule payloads such as proteins and growth factors (Figure
3.4D). These systems provide diffusive release kinetics that may be tuned through
network properties such as porosity, mesh size, and degradation, which may in part be
mediated by dynamic supramolecular interactions. For example, Liu et al used
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polyrotaxane assembly between αCD and tri-block copolymers to form gels that display
tunable sustained release of dextran molecules as a model for release.101 Furthermore,
the Scherman group developed systems based on CB[8] assembly that provide tunable
release of bioactive proteins over sustained periods in vitro, as previously discussed.85
Finally, work from the Hennink group as well as our own have shown tunable protein
release from βCD-based hydrogels, where crosslink density was used to control release
for up to 60 days.65,102 These applications have recently been extended in vivo, where
the guest-host hydrogel was used as an injectable material for diffusive local delivery of
multiple biomolecules (interleukin-10 and anti-transforming growth factor β) to treat
chronic kidney injury.103 Similarly, hydrogels composed of αCD pseudopolyrotaxanes
with PEO terminated block copolymers have been used as an injectable reservoir for
delivery of erythropoietin (EPO) in a rodent model of MI. The therapy resulted in a
tendency toward increased vascular density as well as a significant decline in apoptosis
and increase in myocardial function (fractional shortening) as compared to saline,
hydrogel alone, and soluble EPO injection. These examples demonstrate the
multifaceted use of such material systems as an easily prepared injectable material to
generate diffusively controlled drug delivery reservoirs in vivo.
A last mechanism by which guest-host interactions can control release of
molecules is through inclusion effects of therapeutics with macrocycles anchored to a
polymer backbone (Figure 3.4E). Several groups have investigated covalently
crosslinked hydrogels containing CD pendant groups to provide sustained release of
small molecules.104-109 In one example, the von Recum group developed polyurethane
gels containing CD as device coatings for the controlled release of numerous
antibiotics.110 Work from our own group has also explored CD retentive effects for
controlled release of small molecules including doxorubicin, doxycycline, and peptides
containing tryptophan residues, from guest-host assembled networks, leveraging these
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interactions to provide materials that are simultaneously injectable and exhibit sustained
release properties.109 These systems provide tunable small molecule release through the
engineering of host content, as well as the guest affinity for the host included in the
network.

Figure 3.4. Guest-host interactions in drug delivery systems. Guest-host chemistry
may be used for direct, non-covalent modification of drug molecules with targeting
ligands (A), to provide non-covalent modification of nanoparticle drug carriers with
targeting or stealth ligands (B), and to impart molecular carrier functionality to
nanoparticles (C). Furthermore, in hydrogel systems, guest-host chemistry may be used
to tune crosslinks in hydrogels for the diffusive release of biomacromolecular
therapeutics (D) or to promote retention of small molecule therapeutics within the
hydrogel (E).
3.3.3. CELL-MATERIAL INTERACTIONS
While the above applications have targeted material implantation and therapeutic
delivery through guest-host mediated assembly, still others have sought to develop
methods for the direct modification of cell-material interactions using guest-host
chemistry. These approaches to modulate cell-material interactions have primarily taken
two forms: modification of material surfaces and the pursuit of material-assisted cell
delivery.
Surface modification strategies are useful to introduce various biophysical and
biochemical signals to cells, and guest-host interactions provide an opportunity to
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introduce dynamic signals that can alter cell behavior. Stupp and colleagues utilized the
guest-host complexation of guest-bound adhesive peptide sequences to alginate-βCD
surfaces to dynamically control biomolecule display.111 Specifically, they utilized the
fibronectin derived cell-adhesion sequence RGD bound to the guest molecule Ad or
naphthalene, suspended in culture medium, to impart cell adhesion and spreading on
the material surface. Importantly, spreading was observed to be dependent on the
affinity of the guest for βCD and was reversible when napthyl-RGD was removed by
competitive binding with the higher affinity non-cell adhesive sequence Ad-RGES. In
concurrent work, the Cooper-White group used supramolecular interactions to display
RGD in nanopatterned topographies produced by the segregation of Ad terminated
polystyrene-co-PEO block copolymers (PS-PEO-Ad).112 Such topographies are known to
influence cell behaviors, including adhesion, spreading, and differentiation.113-115 The
ratio of PS-PEO/PS-PEO-Ad used to control the concentration of βCD-RGD bound
within the nanodomains influenced cell adhesion and area. Interestingly, the facile
conjugation process enabled the concurrent addition of RGD and the laminin derived
sequence IKVAV in set molar ratios, demonstrating similar adhesion across all ratios
with spreading and stress fiber organization dependent on RGD concentration alone.
These methods of dynamic surface modification have demonstrated promise
toward influencing cell adhesion and spreading; however, little work has been performed
to directly demonstrate influence over cell differentiation. There is a growing interest in
the field to understand the effects of substrate properties on differentiation, as indicated
by the recent use of covalently or ionically crosslinked hydrogels with tunable viscous
behaviors (i.e., creep and viscoelasticity) to study differentiation.116-118 Toward
understanding differentiation in response to mechanically dynamic substrates, αCD-PEO
polyrotaxane coated surfaces have recently been explored. Here, the mobility of αCD
was modulated by methacrylation—thus varying its affinity for PEO. Subsequent coating
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of this polyrotaxane surface by fibronectin produced a cell-adhesive surface which
demonstrated enhanced osteogenic differentiation in response to molecular mobility.
Though, results are complicated by a lack of standardization in fibronectin density
between groups.119
Cell delivery for therapeutic applications is often problematic, as cells have
limited retention at injection sites; however, hydrogels can be used to enhance cell
retention, particularly with rapidly re-assembling hydrogels.88,120 Toward such a delivery
approach, Kimoon Kim

and colleagues have developed an in situ forming

supramolecular hydrogel (Figure 3.5) based on the interaction of hyaluronic acid
modified by CB[6] and alkylammonium ions 1,6-diaminohexane (DAH) or spermine
(SPM). Initial studies demonstrated the rapid formation of a hydrogel upon mixing of
CB[6]-HA with either DAH-HA or SPM-HA, though SPM-HA hydrogels exhibited
significant toxicity toward fibroblasts in culture. In contrast, DAH-HA hydrogels exhibited
good cytocompatibility and fibroblast proliferation was observed when hydrogels
included the cell adhesive RGD sequence which was modularly included by guest-host
interaction through preparation and addition of c(RGDyK)-CB[6].86 Building upon this
work, they utilized the materials as a platform for the delivery of engineered
mesenchymal stem cells (eMSCs) for suppression of tumor growth.121

The authors

engineered MSCs to produce interleukin-12 (IL-12) through adenoviral transfection and
demonstrated increased IL-12 production by hydrogel inclusion of retinoic acid (RA,
hydrolytically bound to HA) and CB[6] conjugated dexamethasone (Dexa-CB[6], guesthost bound). Assessment of enhanced green fluorescent protein (EGFP) expression in a
subcutaneous injection model demonstrated cell retention and continued protein
expression beyond 60 days, greater than three-fold longer than control hydrogels.
Delivery of IL-12 producing eMSCs in a subcutaneous murine melanoma model was
successful in retarding tumor growth and enhancing survival outcomes. Importantly, this
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effect was enriched by inclusion of Dexa-CB[6] and RA, demonstrating the utility of
supramolecular drug inclusion.
While these studies by the Kim group have utilized sequential injection of the
hydrogel precursors and in situ hydrogel formation, such approaches may be enhanced
by a priori hydrogel formation in the presence of cells and subsequent shear-thinning
delivery. Indeed, numerous shear-thinning hydrogel systems have increased delivery
efficiency both by increasing cell viability and retention at the target site. Toward these
efforts, the use of shear-thinning hydrogels based on CD-HA and Ad-HA, previously
discussed, have been used to encapsulate and deliver endothelial progenitor cells
(EPCs) to myocardial infarct tissue in rodents. Results demonstrated enhanced
engraftment of the EPCs with hydrogel delivery (via constitutive GFP expression) at 1
week post-injection when compared to injection of suspended EPC controls. The cellhydrogel therapy likewise resulted in enhanced vasculogenesis and contractile function
when compared to controls of saline, EPC suspension, and hydrogel alone injections.122
While results from such studies are promising, there is still much work to be done to
optimize injection conditions of guest-host systems to make certain that viable cells are
being delivered.

However, it is known that guest-host type hydrogels exhibit

characteristic shear-thinning and shear-banding, similar to other supramolecular
hydrogels where such studies have been performed. For example, in alternative
supramolecular systems such as in β-hairpin peptide hydrogels, shear-thinning behavior
resulted in plug-flow through cylindrical channels (mimicking injection through a needle
or catheter), which reduced exposure of encapsulated cells to shear stresses and
increased viability.123 Continuation of this work in loosely crosslinked alginate hydrogels
has highlighted the importance of extensional flow, such as near entrance to the syringe
needle, as a primary cause of acute cell death.The124 Extension of these studies toward
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direct assembling guest-host hydrogels is essential toward understanding cell viability
with respect to clinical applications of cell delivery.

Figure 3.5. Schematic representation of in situ supramolecular hydrogel
formation. Schematic of cell encapsulation (A), through mixing of cucurbit[6]urilconjugated hyaluronic acid (CB[6]-HA) and polyamine-conjugated HA (PA-HA) and
subsequent modular modification with various CB[6] bound tags. The chemical
structures (B) of CB[6] and PAs of diaminohexane (DAH) and spermine (SPM). Adapted
from Sun et al. 83

3.4. CONCLUSIONS
Supramolecular guest-host chemistry has made great strides over the past
decades since formalization of synthetic methods for their production and subsequent
polymer modifications. Particularly in the field of bioengineering, these unique
chemistries have shown great potential toward numerous applications. Arguably, the
most advanced of these is therapeutic delivery, where the use of cavitands (cyclodextrin
in particular) to enhance solubility and bioavailability of pharmaceutical drugs has
become common practice. However, the capacity to harness these interactions for drug
delivery systems (i.e. nanotherapeutics, drug-eluting coatings, and bioresponsive
materials) currently remains primarily limited to basic research. Similar to alternative
methods

of

now

conventional

delivery,

such

as

liposomal

formulation

of

chemotherapeutics, these methods hold promise as a means to revolutionize the
pharmaceutical industry; though, their development to industrial scale and market
approval remains a challenge.
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At a more basic level, the use of guest-host materials as injectable therapeutics
is of great interest to the medical community. Such material systems perpetuate
numerous applications, including the local delivery of biomolecular therapeutics via
diffusion and the supramolecularly controlled delivery of small molecules or suitably
modified biomolecules. The use of such materials may also be of interest in tissue
bulking applications (e.g., dermal fillers, regenerative scaffolds) and therapeutic cell
delivery. However, the investigation of these important material systems and
applications is mainly limited to in vitro investigation, with exceedingly few examples
demonstrating in vivo efficacy. Further investigation of the in vivo material properties is
needed to develop an understanding of material degradation, mechanics, and
therapeutic elution. Similarly, the biological response to guest-host materials, including
macrophage recruitment and long-term fibrotic encapsulation remains almost wholly
unexamined. Further understanding of these systems in a functional, biological setting is
a needed priority in the field.
Finally, with respect to basic biological understanding—guest-host assembly offers a
unique platform for investigation of cell behavior in response to substrates that mimic
aspects of the dynamic ECM. This is embodied in the capacity to dynamically alter cell
culture substrates, including to mimic features such as adhesion ligand mobility and
substrate viscoelasticity in an attempt to represent more biomimetic cellular
environments. Toward the applications discussed herein, understanding of the
underlying chemical processes and polymer physics are of utmost importance, as they
ultimately control the bulk material properties to enable dynamic, tunable, and
responsive materials and bioconjugated systems.
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CHAPTER 4
SUSTAINED SMALL MOLECULE DELIVERY FROM SUPRAMOLECULAR
HYALURONIC ACID HYDROGELS THROUGH GUEST-HOST MEDIATED
RETENTION

Adapted from:
Mealy JE, Rodell CB, Burdick JA. Sustained small molecule delivery from injectable
hyaluronic acid hydrogels through host–guest mediated retention. Journal of Materials
Chemistry B. 2015;3(40):8010-9.

4.1. INTRODUCTION
Towards the development of translational, multifaceted strategies for treating
disease, self-assembled hydrogels provide unique properties to deliver therapeutics
(e.g., cells, drugs) to tissues. Self-assembly, driven through non-covalent interactions,
may impart shear-thinning and self-healing properties to hydrogels, which allows direct
injection into tissues. A number of non-covalent interactions have been investigated to
form self-assembled hydrogels, including hydrophobic interactions or guest-host
assembly of macrocycles such as cucurbiturils and cyclodextrins (CDs).1-3
CDs are cyclic macromolecules formed from 6, 7, or 8 α-D-glucopyranoside
units, termed α-, β-, and γ-CD respectively. As a strategy for self-assembly, these
molecular interactions have been employed to form hydrogels between polymers
modified with β-CD and adamantane (Ad), α-CD and PEG, and β-CD and azobenzene,
among other polymer systems.3-5 These self-assembled hydrogels have been used
towards a number of biomedical therapies, including mechanical interventions, cell
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delivery, and sustained therapeutic release.6-9 CD guest-host chemistry has previously
been used in the design of drug delivery systems. Notably, the Davis group has
developed cationic CD polymers that ionically complex with nucleic acids to form
nanoparticles, that may be functionalized with targeting ligands via Ad interactions to
promote receptor-mediated endocytosis.10 Regarding sustained release, self-assembled
hydrogels provide easily injectable depots of therapeutics; however, their investigation
as drug delivery systems has largely been focused on macromolecules where release is
governed through network properties. Despite recent advances in supramolecular
systems, few supramolecular hydrogels have been investigated for small molecule
release, due to difficulties associated with using these traditional mechanisms (e.g.
matrix erosion, control of mesh size) to sustain the release of small molecules.
Small molecule therapeutics are potent drugs that can be used in such strategies
as chemotherapy or the inhibition of pathologic matrix metalloproteinase (MMP) activity,
where there is a need for systems that permit localized and sustained therapeutic
delivery.11 Due to the highly hydrated nature of hydrogels and their large mesh size,
most small molecules will diffuse out rapidly in a matter of hours, which is often too fast
to provide sustained therapeutic effects. To address this challenge, strategies using
composite systems of hydrogels and hydrophobic micro/nanoparticles or covalent
conjugation of drugs to polymer backbones have been developed to provide sustained
small molecule release.12 While these strategies are effective, they require added
complexity in hierarchical formulation or offer regulatory translational limitations by
modifying drug molecules. A third strategy that may be used to sustain small molecule
release is to engineer non-covalent affinity between small molecules and polymers to
increase retention time. Hydrogels using affinity mediated sustained release have
recently been developed leveraging interactions between therapeutic peptides or
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hydrophobic molecules and polypeptide-based hydrogels, as well as between
macrocycle hosts and guest ligands.7,13,14
CDs have remarkable affinity for a wide variety of small molecule guests, which
has led to the use of CDs as excipients in a number of small molecule
pharmaceuticals.15,16 In addition, these guest-host interactions have been leveraged to
increase molecule retention within covalently crosslinked hydrogels.14,17-20 In one
example, antibiotic release was sustained for ~10 days from covalently crosslinked
polyurethane hydrogels of β-CD and multivalent isocyanates that were used to coat
metal screws and polymer meshes.14,21 β-CD also forms inclusion complexes with a wide
variety of other molecules, including chemotherapeutics such as doxorubicin, MMP
inhibitors such as doxycycline, and even aromatic amino acids such as tryptophan.22-26
However, β-CD inclusion complexes have not yet been leveraged to provide sustained
small molecule release from hydrogels formed via supramolecular self-assembly.
Recently, our group developed a two component supramolecular hydrogel
formed from hyaluronic acid (HA) modified with Ad (Ad-HA) and HA modified with β-CD
(CD-HA).3 HA is a natural component of the extracellular matrix, which interacts with cell
surface receptors and can even provide stem cell recruitment.27,28 We hypothesized that
alterations in CD content and payload affinity for CD would alter the release of molecules
from hydrogels (Figure 4.1). Such a system combines the unique shear-thinning and
self-healing properties previously reported in these hydrogels with the unique guest-host
inclusion capability of β-CD for a number of small molecule drugs.
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Figure 4.1. Scheme for tuning release of small molecules from drug loaded
supramolecular hydrogels. Ad-HA and CD-HA macromers were synthesized and
evaluated for functionalization (x/[x+y]) using 1H-NMR. Macromers were dissolved in
solutions containing varying drugs (green = high affinity for CD, red = low affinity for CD)
and combined in varying ratios (Ad:CD) to produce bulk hydrogels. Release kinetics
were tuned by varying the CD content available for drug binding or by altering the affinity
of the loaded drug for CD.

4.2. METHODS
4.2.1. MATERIALS
Sodium hyaluronic acid (HA, 90kDa) was purchased from Lifecore (Chaska, MN).
β-cyclodextrin (CD), 1-adamantane acetic acid, and hexanediamine (HDA) were
purchased from TCI America (Portland, OR). Fluorenylmethyloxycarbonyl (FMOC)
protected

amino

dimethylmethaniminium

acids

and

(1H-Benzotriazol-1-yloxy)(dimethylamino)-N,N-

hexafluorophosphate

(HBTU)

were

purchased

from

Novabiochem (Billerica, MA). All other materials were purchased from Sigma-Aldrich (St
Louis, MO).
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4.2.2. MACROMER SYNTHESIS
Ad-HA was synthesized according to previously reported protocols.3 Briefly, HA
was first converted to a tetrabutylammonium salt (HA-TBA) through the use of an ion
exchange resin (Dowex 50Wx4). HA was dissolved in DI water at 3 wt% and mixed with
the resin for 4 h to allow for ion exchange. The resulting solution was filtered, neutralized
with tetrabutylammonium hydroxide, frozen, and lyophilized to produce the HA-TBA salt.
To synthesize Ad-HA, HA-TBA, 4-methylaminepyridine, di-tertbutyl dicarbonate and Ad
were then dissolved using dimethyl sulfoxide (DMSO) and allowed to react for 20 h at 45
°C under nitrogen. The resulting Ad-HA product was then purified by dialysis against DI
water for 3 days, precipitated in acetone, and then further dialyzed against DI water for a
total of 2 weeks. The aqueous polymer solution was then frozen, lyophilized, and
analyzed for purity and percent modification using 1H-NMR (DMX 360, Bruker, Billerica,
MA). All Ad-HA used in this study had ~25 % of HA repeat units modified with Ad
groups (Figure 4.2).
To facilitate conjugation to HA, β-CD was aminated using an HDA linker. First, βCD was tosylated through the reaction of p-toluenesulfonyl chloride and β-CD in
aqueous solution. Sodium hydroxide (3 mol NaOH/ mol CD) was added dropwise to the
solution and stirred for 30 min at room temperature. Next, ammonium chloride was
added to adjust the pH to ~8.5 and precipitate the β-CD tosylate. β-CD tosylate was
repeatedly washed in water and acetone and then dried under vacuum to use in the
amination reaction. A 2-neck flask was charged with β-CD tosylate, HDA, and DMF. The
flask was connected to a condenser, purged by nitrogen, and reacted for 16 h at 80 °C.
CD-HDA was purified by repeated washes with acetone and diethyl ether to yield
aminated β-CD (CD-HDA). To form CD-HA, HA-TBA, CD-HDA, and (benzotriazol-1ylozy)tris(dimethylamino)phosphonium hexafluorophosphate were dissolved in DMSO in
a round bottom flask. The reaction was allowed to proceed for 3 h at room temperature.
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CD-HA was then purified by dialysis against water for 2 weeks, frozen, lyophilized, and
characterized using 1H-NMR. CD-HA used in this study was modified at ~35 % of HA
repeat units for calorimetry experiments and ~25 % for all other experiments (Figure
4.2).
Methacrylated HA (MeHA) was synthesized according to previously reported
protocols.29 Briefly, sodium HA was dissolved in DI water and methacrylic anhydride was
added incrementally to the solution, while maintaining the pH between 7.5 - 8.5 for 5 h.
The solution was then dialyzed extensively against DI water, frozen, lyophilized, and
characterized using 1H-NMR. MeHA used in this study was modified at ~30 % of HA
repeat units (Figure 4.2).
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b

c

Figure 4.2. NMR spectra for various modifications of HA. 1H-NMR for CD-HA (a),
Ad-HA (b), and MeHA (c).
4.2.3. PEPTIDE SYNTHESIS
Peptides were synthesized using standard solid phase synthesis on a solid
phase peptide synthesizer (PS3, Protein Technologies Inc., Tuscon, AZ). Two
fluorescein modified peptides, GKWEWKWE-FITC (3W) and GKGEGKGE-FITC (NoW)

76	
  

were synthesized as model drugs that have a high or low affinity for β-CD, respectively.
Peptides were synthesized on a glycinol 2-chlorotrityl resin and with FMOC protected
amino acids. Peptides were cleaved in a mixture of trifluoroacetic acid, triisopropylsilane,
and water (95:2.5:2.5) and then purified through precipitation in cold diethylether. Solid
peptides were dissolved in DI water, frozen, and lyophilized. Peptide purity and
sequence were confirmed using MALDI-TOF spectroscopy (Multiflex, Bruker, Billerica,
MA). Masses for both 3W (expected 1549.6, m/z 1571.8, corresponding to a complex
with Na ion) and NoW (expected 1162.1, m/z 1162.6) confirmed successful peptide
synthesis.

4.2.4. HYDROGEL PREPARATION
Hydrogels were prepared by first dissolving CD-HA and Ad-HA in phosphate
buffered saline (PBS) or PBS containing drug overnight at room temperature. The CDHA and Ad-HA solutions were mixed to induce gelation. For notation, hydrogels are
referred to as x:y (z wt%) hydrogels, with x:y referring to the Ad:CD stoichiometric ratio
within a given hydrogel, and z wt% referring to the total macromer weight percent of the
hydrogel. All guest-host hydrogels were made using 25 % modified CD-HA and 25 %
modified Ad-HA.
MeHA hydrogels were formed through a photoinitiated radical polymerization of a
macromer solution. MeHA at 7.8 wt% macromer concentration was dissolved in PBS
containing fluorescent peptides and 0.05 wt% I2959 photoinitiator. MeHA macromer
solution was then stored under nitrogen and polymerized using UV light at 10 mW/cm2
for 5 min to induce gelation.
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4.2.5. ISOTHERMAL TITRATION CALORIMETRY
Isothermal titration calorimetry (ITC) was performed using a low volume
isothermal titration calorimeter (Microcal iTC200, Worcestershire, UK). Briefly, aqueous
polymer solutions at 1 mg/mL and 0.468 mg/mL for CD-HA and HA, respectively, were
titrated in 2 µL aliquots to a thermal cell filled with 200 µL of tryptophan at 40 µM.
Differential power was recorded between the sample cell and a reference cell containing
MiliQ water at a constant temperature of 25 °C. Baseline titrations of polymer solution
into MilliQ water were subtracted in order to remove heats of dilution associated with
polymer solution injection. The resulting isotherms were analyzed with Origin 7 software
according to a one-binding site fit to determine association constants. In order to reduce
errors associated with fitting multiple parameters (K, ΔH, n), stoichiometry was predefined according to CD modification determined through 1H-NMR.

4.2.6. RHEOLOGY
Hydrogel mechanics were assessed using a stress-controlled rheometer
(AR2000, TA Instruments, New Castle, DE). Oscillatory time sweeps were conducted at
0.1, 1, and 10 Hz at 1% strain. Additionally, oscillatory frequency sweeps were
performed between 0.01 Hz and 100 Hz at 1 % strain. Finally, to simulate injection,
hydrogels underwent a cycle of strain between 1 % (low strain) and 500 % (high strain)
at 1 Hz. Storage and loss moduli were analyzed for both drug loaded and unloaded
hydrogels.

4.2.7. FLUORESCENCE RECOVERY AFTER PHOTOBLEACHING
Fluorescence

recovery

after

photobleaching

(FRAP)

experiments

were

conducted on a confocal microscope (TCS SP5, Leica, Wetzlar, Germany). In each
experiment, 20 µL hydrogels were placed on glass slides and covered with a glass cover

78	
  

slip. The 488 nm line of an argon laser was set to 50 % power and all images were taken
using the 10x objective with the pinhole fully opened. Pre-bleach images were recorded
over 2 seconds using 0.1 % transmission. A 30 µm diameter region was then bleached
for 4 seconds using 100 % transmission. Post-bleach images were then recorded with
the laser returned to 0.1 % transmission for 230 s of recovery. Data was analyzed using
a custom MATLAB script that fit recovery profiles using nonlinear least squares
regression to the Soumpasis equation:

F(t) = k • e

−

τD
2t

* $ τ D ' $ τ D ', I0 & ) + I1& )/
+ % 2t ( % 2t (.

(1)

where 𝐹 𝑡   is the normalized fluorescence recovery profile, 𝑘  is the mobile fraction, τ D

€

represents the characteristic diffusion time (s), 𝑡  represents time (s), and 𝐼!   and 𝐼!   are
zero and first order modified Bessel functions of the first kind.30 Effective€diffusivities
were then calculated according to:

Deff =

w2
τD

(2)

€
where 𝐷!""   is the effective
diffusivity (µm2 s-1) and 𝑤 represents the bleach spot radius
(µm). This protocol was adapted from previous work conducting similar analyses.31

4.2.8. MOLECULE RELEASE PROFILES
Release assays were conducted in custom made acrylic erosion cells. Erosion
cells were fabricated with a 4.3 mm diameter hydrogel chamber overlaid with a 1.6 cm
diameter supernatant chamber, each chamber having depths of 7 mm and 10 mm,
respectively. 30 µL of the hydrogel was deposited in the chamber, the chamber was
centrifuged to provide an even hydrogel surface, and the hydrogel was covered with 1
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mL of PBS. Once loaded, erosion cells were stored in an incubator at 37 °C.
Supernatant was collected at regular intervals and replaced with fresh PBS. Molecule
release was determined with a plate reader (Infinite M200, Tecan, Männedorf,
Switzerland). FITC labeled peptides were analyzed using 495/525 nm excitation
emission, doxycycline was analyzed using 350 nm absorbance, and doxorubicin was
analyzed using 480/590 nm excitation/emission. At the end of each assay, any
remaining hydrogel was collected along with supernatant and disassociated with addition
of 5 mg/mL Ad solution in DMSO to obtain final fluorescence/absorbance readings.
Fluorescence and absorbance values were then compared to standard curves to
determine total molecule release.

4.2.9. STATISTICAL ANALYSIS
Affinity measurements are presented as an average of affinity constants
determined from n = 3 isotherms per trial. Mechanical measurements are presented as
an average and standard deviation for n = 3 samples. FRAP measurements were
conducted for n = 4 recovery profiles, and presented as average effective diffusivities
and standard deviations. Release profiles are presented as average cumulative percent
release and standard deviation of cumulative release for n = 4 samples. Statistical
analyses on ITC and rheology measurements were conducted using two-tailed student t
tests. One-way ANOVA with post-hoc Tukey’s Honestly Significant Difference testing
was conducted on diffusivity measurements using R.
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4.3. RESULTS AND DISCUSSION
4.3.1. SMALL MOLECULE BINDING TO HA
HA was successfully functionalized with CD to produce CD-HA, with ~35 % of HA
repeat units modified. It was first investigated whether CD modification of HA could
increase the polymer affinity for small molecules, using ITC. As a representative small
molecule, L-tryptophan was used to investigate this interaction, due to its aromatic
structure, hydrophobic nature, and previous investigation of affinity with CD.15,24,26
Additionally, as a natural amino acid, L-tryptophan presents an interesting binding target,
as it allows for peptide design with natural compounds that may promote polymer
affinity.
Isotherms produced by CD-HA and unmodified HA titrations were vastly different
(Figure 4.3 a,b). CD-HA produced a distinct exothermic reaction upon mixing with
tryptophan in the sample cell, while unmodified HA remained at near baseline levels for
all injections. Isotherms were quantitatively analyzed in Origin 7 software by a onebinding site model fit to determine the apparent association constant (KA) between the
polymer and tryptophan. The binding site stoichiometry value (n) was set to 0.35 to
account for CD modification as determined by 1H-NMR and to reduce error associated
with fitting multiple parameters. Fits for isotherms of CD-HA and tryptophan produced an
average KA of 1.6×104 ± 2.9×103 M-1. While this value is slightly higher than previously
reported values for this interaction, the increase may be attributed to changes in CD
chemistry upon conjugation to HA, as it has been shown that these changes can alter
binding affinities to tryptophan.26 Accurate values for KA were not attainable in
unmodified HA isotherms due to high error associated with parameters obtained from
fits, which is attributed to randomly scattered integrated heat values resulting from near
baseline heat changes for all injections. Taken together, these data suggest that
modification of HA with CD provides a multiple orders of magnitude increase in affinity
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for tryptophan. Since the cyclic domains such as the indole moiety found in tryptophan
are found in many pharmacologic small molecules, this increase in affinity suggests that
HA modification would allow increased affinity for many small molecules.32
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Figure 4.3. Isothermal titration calorimetry for HA binding to tryptophan. Solutions
of HA (either unmodified or modified with CD) dissolved in MilliQ water were titrated into
40 µM tryptophan in MilliQ water. Baseline isotherms of modified or unmodified HA into
water were subtracted to account for heats of dissolution. Representative isotherms and
chemical structures of binding components are shown for (a) unmodified HA binding to
tryptophan or (b) CD-HA binding to tryptophan.

4.3.2. EFFECT OF DRUG LOADING ON HYDROGEL MECHANICS
HA was also successfully modified with Ad groups to form Ad-HA. Gelation
occurred instantaneously upon mixing of CD-HA and Ad-HA macromer solutions,
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through guest-host interactions of Ad and CD groups.

Since incorporated small

molecules also complex with CD, it is important to understand the competitive effect of
drug loading on hydrogel mechanics. As a model drug, a peptide modified with
tryptophan and FITC (termed 3W, due to 3 tryptophan residues per peptide) was loaded
(1 mg/mL) into 1:1 (5 wt%) hydrogels. This notation of the form ‘x:y (z wt%)’ refers to the
molar ratio of Ad:CD in the hydrogel (x:y) and the total polymer weight percent in the
hydrogel (z). This formulation was selected for mechanical testing since it would have
the greatest chance to reduce hydrogel mechanics with drug loading, as the Ad:CD ratio
is 1:1. The loading concentration for 3W of 1 mg/mL is at the peptide solubility limit and
is ~5 % of the total CD content in the hydrogel. Furthermore, this concentration is orders
of magnitude higher than loading concentrations used in subsequent release assays.
Please note that the peptide was not designed for any bioactivity, but rather for use as a
model molecule to investigate the influence of hydrogel design on diffusivity and release.
To examine the effect of molecule incorporation on hydrogel mechanical
properties, frequency response profiles for G’, G”, and tan(δ) were obtained. Hydrogels
displayed frequency responsive behaviors that are characteristic of self-assembling, twocomponent systems (Figure 4.4a). Both molecule-loaded and unloaded hydrogels
exhibited similar frequency response profiles for these parameters, showing qualitative
similarity in mechanics. Time sweeps were conducted to assess differences between
these two groups in shear and loss moduli at 0.1 Hz, 1 Hz, and 10 Hz. Both formulations
displayed frequency responsive increases in storage moduli (Figure 4.4b) and loss
moduli (Figure 4.4c) and there were no significant differences in either storage or loss
moduli (p > 0.05) between the formulations. One explanation for the lack of difference in
bulk mechanics with and without encapsulated small molecules is the relative difference
in affinity of tryptophan for CD as compared to AD. The association constant for the AdCD complex has been reported to be as high as 105 M-1, orders of magnitude higher
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than previous reports for tryptophan-CD, suggesting that there would be minimal
competition between the two.15,26 Considering that a wide variety of small molecules
complex with CD on the same order of magnitude as tryptophan, it is unlikely that
loading of therapeutics would compete with the formation of the Ad-CD complex and
cause a decrease in hydrogel mechanics.15
Finally, loaded hydrogels were subjected to a cyclic strain protocol, whereby
hydrogels were placed under cycles of high and low oscillatory strain to simulate
conditions during injection and recovery after injection. This technique has been used
previously to examine network disassembly and reassembly in self-assembling systems
from a mechanical perspective.33-36 Hydrogels showed a rapid decrease in storage
modulus under high strain, indicating a reduction in elastic properties and a more fluidlike behavior, as well as a rapid recovery of the storage modulus under low strain,
suggesting a return to a more elastic, gel-like state (Figure 4.4d). Hydrogels loaded with
the peptide rapidly assembled after injection, indicating that there would be minimal
extravasation during administration (Figure 4.5). These characteristics are important in
the development of translational therapies, so that both hydrogel and drugs may be
precisely localized. This aspect can be challenging with alternative injectable hydrogels
that covalently crosslink at the injection site, as hydrogels may clog the delivery device if
gelation occurs too quickly or may diffuse from the injection site prior to gelation if
gelation is too slow.6
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High Strain

Low Strain

c

Figure 4.4. Comparison of mechanical properties in unloaded and drug loaded
(3W peptide, 1mg/mL) hydrogels (1:1 (5 wt%)). (a) Representative frequency sweeps
showing G’ (unloaded=blue solid circles, loaded=red solid squares), G” (unloaded=blue
open circles, loaded=red open squares), and tan(δ) (unloaded=black open circles,
loaded=black crossed squares). (b) Average G’ values for time sweeps for unloaded
(blue) and loaded (red) hydrogels for 0.1Hz, 1Hz, and 10Hz frequencies. (c)
Representative cyclic strain experiment showing G’ (red solid line), G” (red dashed line),
and strain (black dotted line) for loaded hydrogels undergoing cycles of low and high
strains.

Figure 4.5. Hydrogel injection. Injection of a 1:2 (7.8 wt%) hydrogel loaded with 100
µM 3W peptide through a 27G needle.
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4.3.3. EFFECT OF MOLECULE AND HYDROGEL PARAMETERS ON DRUG
MOBILITY
Fluorescence recovery after photobleaching experiments were used to assess
encapsulated molecule mobility within hydrogels as a function of hydrogel parameters
and molecule interaction with CD. Using this technique, small regions of hydrogels
loaded with mobile fluorescent payloads were bleached with a high intensity laser. The
recovery of fluorescence due to diffusion of unbleached molecules into the region was
then monitored and quantified to determine the diffusivity of the fluorescent payload
within the hydrogel. Two fluorescently labeled peptides were used in these experiments:
a high affinity peptide for CD (3W), as well as a lower affinity peptide, in which the
tryptophan residues were replaced with glycine (NoW, GKGEGKGE-FITC). These
peptides were used as model drugs to represent payloads of varying molecular affinities,
and were loaded into hydrogels at 100 µM.
To assess the influence of hydrogel formulation on molecule mobility, CD content
within hydrogels was altered by increasing the overall CD-HA concentration (1:1 (5
wt%), 1:2 (7.8 wt%), and 1:3 (10.5 wt%)). As CD concentration increased, the effective
diffusivity of the 3W peptide significantly decreased within the hydrogel (Figure 4.6a).
These data suggest that the increase in CD-HA content does reduce peptide mobility
within the hydrogel. To address the potential confounding effects that an increase in total
macromer concentration may have on mobility, an additional formulation at a 1:2 Ad:CD
ratio was compared to the 1:1 Ad:CD ratio, with both hydrogels at 5 wt%. The 1:2 Ad:CD
formulation showed significantly lower effective diffusivities than the 1:1, despite
maintaining a similar total macromer concentration of 5 wt% (Figure 4.6b). This
comparison suggests that the CD-HA component itself is a significant contributor to
molecule diffusivity, which is supported by the binding affinity results quantified by ITC
analysis.
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To further investigate this affinity mediated reduction in mobility, we explored the
effect of removing the tryptophan residue from the 3W peptide by using the NoW
peptide. A 1:2 (7.8 wt%) hydrogel was loaded with 100 µM NoW peptide and compared
to a similarly formulated hydrogel with 100 µM 3W peptide.

It was observed that the

NoW peptide had significantly higher diffusivity in the same hydrogel when compared to
the 3W for the given 100 µM concentration (Figure 4.6c). These results can be
observed visually in Figure 4.6d. Both peptides were bleached with similar efficiencies
(1 s), but show differences in recovery profiles (3 s and 8 s) until both reach almost full
recovery (30 s). The influence of peptide chemistry on mobility further implies the
importance of CD affinity in controlling peptide mobility in these hydrogels.
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Figure 4.6. Fluorescence recovery after photobleaching experiments. Hydrogels
loaded with fluorescent peptides were assessed with FRAP analysis to determine
payload mobility within the hydrogel. Diffusivity of fluorescent peptide payloads in
hydrogels was assessed with changes in (a) CD-HA wt%, (b) Ad:CD ratio at a total
polymer concentration of 5 wt%, and (c) payload chemistry (3W versus NoW). (d)
Representative FRAP images for changes in payload chemistry, scale bar = 50 mm.
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4.3.4. EFFECT OF MOLECULE AND HYDROGEL PARAMETERS ON BULK
RELEASE PROFILES
Towards investigating the small molecule sustained release properties of these
hydrogels, we next investigated the effect that both hydrogel and payload parameters
have on bulk release profiles. As in the FRAP experiments, groups were selected to
compare the effects of increasing CD-HA concentration, increasing the Ad:CD ratio for a
given total weight percent, and changing the relative affinity of a fluorescently labeled
payload. In order to provide a contrast to this affinity-based interaction, release from a
covalently crosslinked hydrogel with no CD content was examined. MeHA hydrogels
containing no CD content were formed through the photoinitated polymerization of 30 %
modified MeHA at 7.8 wt% and containing 100 µM of the 3W peptide. Peptide release
into PBS was examined over 8 days. This profile (Figure 4.7) showed ~90 % release in
the first 24 h and exemplifies the issues with sustaining small molecule release from
traditional swollen hydrogels.

Figure 4.7. Cumulative 3W release. 3W release from covalently crosslinked hydrogel
containing no cyclodextrin (MeHA).
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Towards investigating the cyclodextrin retentive effect in our hydrogels, several
formulations were explored. All supramolecular hydrogels discussed here were loaded
with 100 µM of peptide. This represents approximately a 1:100 ratio of peptide to CD
available for binding (i.e., CD that has not been paired with Ad) in a 1:2 (7.8 wt%)
system. This ratio is consistent with values investigated in previous modeling studies
investigating affinity mechanisms in drug release.37 The effect of increasing CD-HA
macromer concentration was assessed in these hydrogels by conducting release
experiments on a 1:1 (5 wt%), 1:2 (7.8 wt%), and 1:3 (10.5 wt%) hydrogels. Results of
these systems are shown in Figure 4.8a. Analogous to trends observed in molecule
diffusivity from FRAP studies, increasing the CD-HA content of these hydrogels
produced slower bulk release kinetics. In the first 24 h, ~70 %, ~35 % and ~20 % of the
initial payload was released for the 1:1 Ad:CD, 1:2 Ad:CD, and 1:3 Ad:CD systems,
respectively. These results are markedly improved over the MeHA system, and show the
increased ability of mismatched systems to sustain the release of small molecule
payloads. Furthermore, even matched systems, where there is an equal molar ratio of
Ad and CD, present some sustained release capabilities. This is likely due to spatial
limitations in the network that prohibit complete consumption of CD by Ad guests,
leaving the remaining CD available to bind to drugs. It should also be noted that only
marginal improvements in sustained release were observed when shifting from 1:2 to 1:3
Ad:CD hydrogels. Likely this is due to an upper limit on retentive effects that can be
achieved through CD-peptide guest-host interactions for this particular payload and
concentration. These materials also displayed moderate erosion during the three-week
assay, and are comparable to our previous reports on the degradation of this material
(Figure 4.9). 3
A comparison of release profiles between a 1:1 (5 wt%) to a 1:2 (5 wt%) hydrogel
(Figure 4.8b) further indicates that the sustained properties are a result of CD content
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within the hydrogel. A mismatched system of the same macromer concentration
produced slower sustained release profiles, which can be attributed to the increased
amount of unbound CD available to bind and retain the peptide. Finally, the effect of
varying peptide affinity on bulk release was investigated. Hydrogels were formulated at
1:2 (7.8 wt%) and 100 µM concentration of either 3W or NoW peptide. Release over 21
days was markedly slower for 3W when compared to the NoW peptide (Figure 4.8c).
However, the NoW peptide still shows some degree of sustained release from these
hydrogels, since CD binds with a number of small hydrophobic moieties such as the
fluorescein dye on NoW. Release data of these peptides with varying structure further
reinforces the importance of CD affinity in these systems.
Overall, these release studies have elucidated a number of properties about
these hydrogels and the release of small molecules. First, our self-assembled hydrogels
provided sustained release of two different peptides for up to 3 weeks. This shows
remarkable improvement over the capacity of traditional systems (i.e., hydrogels without
a drug affinity component) to sustain the release of molecules of this size (Figure 4.7).
These systems have tunable profiles that can be changed through a number of
parameters. Engineering molecule affinity is one mechanism that can provide specific
control of release profiles on a drug-to-drug basis. This is useful particularly in the
delivery of peptide therapeutics, as these can be readily engineered with groups such as
tryptophan that will promote the appropriate release profile. Finally, and most
importantly, by varying the amount of CD-HA macromer in these hydrogels, the extent of
molecule retention and subsequent release can be easily controlled. These multiple
controllable parameters allow for potential tunability over a wide range of molecules as
payloads.
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Figure 4.8. Release profiles of entrapped peptides. Hydrogels containing fluorescent
peptides were injected in custom designed erosion cells and peptides released into PBS
were quantified. Cumulative release profiles were determined in gels with changes in (a)
CD-HA wt%, (b) Ad:CD ratio at total polymer concentration of 5 wt%, and (c) payload
chemistry (3W versus NoW). Insets show an expanded view of time points collected
during the first 5 days.
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Figure 4.9. Hydrogel degradation. Hydrogel erosion for matched and mismatched CDHA/Ad-HA systems.
4.3.5. SUSTAINED RELEASE OF DOXYCYCLINE AND DOXORUBICIN
To

show

the

application

of

these

systems

towards

small

molecule

pharmacologics, two clinically used small molecule therapeutics (i.e., DOX, DXY) were
investigated. These drugs were selected as DOX is a chemotherapeutic that acts
through intercalating with DNA and DXY has been investigated as an MMP inhibitor,
both classes of drugs that benefit from localized delivery and both been shown
previously to form complexes with CDs and their derivatives.22,25,38-40 Both the 1:1 (5
wt%) and a 1:2 (7.8 wt%) hydrogel formulations were investigated for release, with drug
loading at 1 mg/mL. DOX release was sustained over the first 14 days of the study
(Figure 4.10a). As observed with fluorescently labeled peptide substrates, increasing
CD-HA content in DOX loaded hydrogels produced a similar reduction in release
kinetics, particularly noticeable during the first week. DXY loaded hydrogels also showed
similar trends to the DOX loaded systems (Figure 4.10b). The sustained release effect
of increased CD-HA content was more pronounced in DXY release profiles, and this
may be attributed to differences in CD affinity between DXY and DOX, which have been
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reported at 503 M-1 and 297 M-1, respectively.22,41 Profiles for the 1:2 Ad:CD formulation
for both drugs also indicate incomplete release of the encapsulated payload, with an
increased fraction of drug retained in the hydrogel at the study endpoints. These data
show the versatility of the presented hydrogel system in delivering a number of small
molecules in a readily translatable manner. As injectable systems, hydrogels providing
sustained release of either of these two molecules could find biomedical applications,
such as in cancer therapies.39,42 Although the work here did not illustrate bioactivity of
released drugs, we do not expect any comprised activity since we have not chemically
modified the drugs and others have shown activity of molecules in delivery systems
leveraging non-covalent inclusion complexes.43,44

a

b

Figure 4.10. Release of doxorubicin (DOX) and doxycycline (DXY) from injectable
hydrogels. Cumulative release of (a) DOX or (b) DXY for 1:1 (5 wt%) (red) or 1:2 (7.8
wt%) (blue) formulations over 3 weeks. Insets show an expanded view of time points
collected during the first 5 days.

4.4. CONCLUSIONS
Here, we have developed a physically assembled hydrogel system for the
tunable and sustained release of small molecules using CD guest-host interactions.
Modification of HA with CD increased affinity for model small molecules by multiple
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orders of magnitude, and this affinity was leveraged to tune the release of peptide model
drugs, as well as doxorubicin and doxycycline, from assembled hydrogels. Furthermore,
hydrogel drug-loading had minimal effects on mechanics and allowed the hydrogels to
retain their injectable and rapid self-assembly properties. Ultimately, the work presented
in this paper shows a small molecule, controlled release system that is rapidly
formulated, easily tuned, and avoids the potential challenges associated with other
injectable delivery systems.
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CHAPTER 5

GUEST-HOST HYDROGELS FOR THE DELIVERY OF SMALL MOLECULE MMP
INHIBITORS TO ATTENUATE LEFT VENTRICULAR REMODELING AFTER
MYOCARDIAL INFARCTION

5.1. INTRODUCTION
Myocardial infarction (MI) is an occlusion of a coronary artery that results in an
ischemic region within the myocardium.1 The heart then undergoes a series of events
that can result in a loss of mechanical function and progression to long-term heart failure
and mortality.2 Specifically, in the days to months after the initial infarction event, the
heart

undergoes

structural

changes,

collectively

known

as left

ventricular (LV) remodeling.3,4 Initiated by the loss of contractile cells and inflammation,
the left ventricle ultimately dilates, the myocardial wall thins, and the infarct region
expands and transitions to scar tissue.5-7 Currently, treatments for MI focus on initial
tissue reperfusion and decreasing the work-load of the heart; however, few treatments
actually address the underlying processes that drive the progression of LV remodeling.1
A major biological process that contributes to LV remodeling is the maladaptive
upregulation of matrix metalloproteinases (MMPs) - proteases that are responsible for
degradation of the extracellular matrix (ECM).5,8,9 The role of MMPs in MI has been
widely investigated over the past two decades and transgenic deletion of MMPs or
systemic inhibition via pharmacologics have shown that MMPs play a key role in
regulating LV remodeling, and ultimately, cardiac dysfunction.4,10-15 MMP upregulation is
a result of early inflammation and altered activity of fibroblasts and other endogenous
cells; while the purpose of this inflammatory response is to promote invasion of
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macrophages to clear cellular debris and to induce new vasculature in the myocardium,
the collateral damage on tissue mechanical properties significantly promotes adverse LV
remodeling.5,6,9 MMP changes are largely localized to the infarcted tissue and are
specific to a small subset of MMPs.14,16
Endogenously, MMP activity is regulated through the activity of the four tissue
inhibitors of matrix metalloproteinases (TIMPs). TIMPs undergo a significant downregulation in MI, concomitant with the aforementioned increase in MMP activity.14
Furthermore, deletion of TIMP-3 in animal models increases LV remodeling and loss of
cardiac function after an MI.17-19 As a means to replicate the function of TIMPs,
numerous small molecule MMP inhibitors have been developed that have broadspectrum or targeted inhibition on a subset of MMPs. These molecules have faced
challenges clinically, frequently producing off-target effects such as musculoskeletal
syndrome (MSS) in patients enrolled in trials with systemic delivery of MMP inhibitors for
indications such as cancer and arthritis.20-22 Due to these concerns, a clinical trial
evaluating the inhibitor PG116800 for treatment of MI, PREMIER, ultimately reduced the
dosing of the inhibitor from initially administered levels.20 While this new dose did not
produce MSS, the drug failed to influence LV geometry and function, likely due to
inadequate concentrations to achieve therapeutic efficacy.
Biomaterials provide an opportunity to localize MMP inhibitors to the tissue of
interest to avoid off-target issues, while maintaining high enough doses for efficacy. For
MI, hydrogels (water-swollen crosslinked polymer networks) are particularly appealing,
due to their diverse properties and potential for injection into cardiac tissue, including
through percutaneous routes. Indeed, numerous hydrogels have already been injected
into the myocardium after MI to impart mechanical stability to the remodeling tissue.23-27
Additionally, hydrogels have been widely explored for local drug delivery, where the
therapeutic is entrapped during gelation and then released based on diffusion and
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degradation

mechanisms.28,29

We

previously

used

this

approach

to

deliver

exogenous TIMP-3 after MI and observed improvements with respect to remodeling and
cardiac function, without spill-over to the circulation.23,30
Beyond the delivery of TIMPs, there is great interest in the local delivery of small
molecule MMP inhibitors, including those that showed promise but were not explored
further due to concerns with systemic delivery. One of these molecules is SD7300, an
MMP inhibitor developed by Pfizer, that has shown potential in preclinical studies to
provide improvements in cardiac outcomes after MI, but there are concerns with offtarget effects such as MSS.31 However, there are particular challenges to the delivery of
small molecules from hydrogels, as their size leads to rapid diffusion from the network.28
To address this, we describe here the development of an injectable hydrogel that
sustains the release of SD7300, through interactions between the hydrogel and the drug.
Further, we investigate delivery and efficacy in an ischemia/reperfusion model of MI in
swine, including delayed percutaneous delivery.

5.2. METHODS
5.2.1. MACROMER SYNTHESIS
All materials were purchased from Sigma-Aldrich unless otherwise indicated.
Hyaluronic acid (HA) (74kDa, Lifecore) was first converted to a tetrabutylammonium salt
(HA-TBA) through the use of an ion exchange resin (Dowex 50Wx4), where HA in
deionized (DI) water was mixed with the resin for 4 h and the product was filtered,
neutralized with tetrabutylammonium hydroxide (TBA), frozen, and lyophilized to
produce the HA-TBA salt. Subsequent synthesis of adamantane modified HA (Ad-HA)
and cyclodextrin modified HA (CD-HA) was conducted according to previously described
protocols.32 HA-TBA, 4-methylaminepyridine, di-tertbutyl dicarbonate and adamantane
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were dissolved in dimethyl sulfoxide (DMSO) and allowed to react for 20 h at 45 °C
under nitrogen to produce Ad-HA, which was purified by dialysis against DI water for 3
days, precipitated in acetone, and then further dialyzed against DI water for a total of 2
weeks. The aqueous polymer solution was then frozen, lyophilized, and analyzed for
purity and modification using 1H-NMR (DMX 360, Bruker, Billerica, MA). All Ad-HA used
in this study had ~25 % of HA repeat units modified with adamantane.
To facilitate conjugation to HA, β-CD was aminated using a hexamethane
diamine (HDA) linker, as described previously to yield aminated β-CD (CD-HDA).32 To
form

CD-HA,

HA-TBA,

CD-HDA,

and

(benzotriazol-1-

ylozy)tris(dimethylamino)phosphonium hexafluorophosphate were dissolved in DMSO in
a round bottom flask. The reaction was allowed to proceed for 18 h at room temperature.
CD-HA was then purified by dialysis against water for 2 weeks, frozen, lyophilized, and
characterized using 1H-NMR. CD-HA used in this study was modified at ~35 % of HA.

5.2.2. HYDROGEL FORMATION AND CHARACTERIZATION
Hydrogels were prepared by first dissolving CD-HA and Ad-HA in phosphate
buffered saline (PBS) or PBS containing the small molecule for encapsulation (i.e.,
SD7300, IR800) and the mixing for immediate gelation. Hydrogels of varying
formulations were generated, containing the relative molar ratios of cyclodextrin to
adamantane of 1:1, 2:1, and 3:1 at 6 wt% total macromer concentration. Hydrogels were
characterized using a stress-controlled rheometer (AR2000, TA Instruments) fitted with a
20 mm diameter cone (0.995° angle) and a 27 µm gap. Oscillatory time sweeps were
conducted at 0.1, 1, and 10 Hz at 1% strain. Additionally, oscillatory frequency sweeps
were performed between 0.01 Hz and 100 Hz at 1 % strain. Continuous flow
experiments were conducted at shear rates ranging from 1 s-1 to 10 s-1. Injection force

103	
  

testing was conducted using an Instron compressive testing apparatus with a 1 mL
syringe and 21G needle, with extrusion rates conducted at 12, 30, and 60 mm/min..

5.2.3. DRUG RELEASE AND ACTIVITY
Release assays were conducted in custom made acrylic erosion cells. Erosion
cells were fabricated with a 4.3 mm diameter hydrogel chamber overlaid with a 1.6 cm
diameter supernatant chamber, each chamber having depths of 7 mm and 10 mm,
respectively. 30 µL of the hydrogel was deposited in the chamber, the chamber was
centrifuged to provide an even hydrogel surface, and the hydrogel was covered with 1
mL of PBS. Once loaded, erosion cells were stored in an incubator at 37 °C.
Supernatant was collected at regular intervals and replaced with fresh PBS. At the end
of the study, any remaining hydrogel was collected along with supernatant and
disassociated with addition of 5 mg/mL Ad solution in DMSO.
Molecule release was determined with a plate reader (Infinite M200, Tecan).
SD7300 content was measured at 270/304 nm excitation/emission and IR 800 was
analyzed at 774/800 nm excitation/emission. Fluorescence and absorbance values were
then compared to standard curves to determine total molecule release. The MMP-2
inhibitory activity of hydrogel releasates was determined using a fluorogenic MMP-2
activity assay. Briefly, rhMMP-2 was activated with 4-aminophenylmerucric acetate for
1h at 37 °C. In a 96 well plate, 50 uL of MMP-2 solution was added to 40 uL of hydrogel
releaseate and incubated for 1 h to allow for binding of SD-7300 to the active site of
MMP-2. Finally, 10 uL of fluorogenic MMP substrate was added to each well, yielding
final concentrations of 0.25 ng/µL MMP-2 and 20 µM fluorogenic substrate. Immediately
after addition of the fluorogenic substrate, samples were read for a 5 min kinetic cycle
with a plate reader at 320/405 nm. The slope of the initial linear portion of this curve was
used as a metric for enzyme activity, and baseline values (i.e., fluorogenic substrate with
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no MMP-2) were subtracted from data points, and values were subsequently normalized
to samples containing no MMP-inhibitor.

5.2.4. PORCINE MI MODEL
Mature pigs (n=19) (Yorkshire, male, 15-20 kg) were administered amiodarone
(200 mg PO) and aspirin (81 mg PO) for 3 days pre-operatively and a broad spectrum
antibiotic (Draxxin, 2.5 mg/kg, IM) at least once pre-operatively. On the day of surgery,
pigs

were

sedated

(ketamine/acepromazine/atropine:

22/1.1/0.04

mg/kg

IM,

respectively), intubated, and then maintained on 1.5-2% isoflurane delivered in an
oxygen/nitrous mixture (3:1 L/min, respectively). Buprenorphine (0.05 mg/kg IM) was
administered as pre-surgery analgesia. An intravenous infusion (via ear vein cannula) of
Benadryl (25 mg) in conjunction with a continuous lidocaine infusion (4 mg/kg/hr) and
lactated ringers solution (10 mL/kg/hr) was initiated. This anesthesia/premedication
protocol prevented refractory arrhythmias during the IR protocol.
The region encompassing the right femoral artery was prepared in a sterile
fashion, the main branch of the femoral artery surgically exposed, and a catheter
introducer (6F Input Introducer Sheath, Medtronic) positioned and stabilized in the
artery. A bolus of heparin was administered (4000 units, IV) prior to placement of the
guide catheter followed by an additional bolus every hour (1000 units, IV). Under
fluoroscopic guidance (GE OEC 9600, UT), a coronary angiography catheter/launcher
(5F Launcher guiding catheter .058" HSI, Medtronic) was placed in the left coronary
ostia, and an angioplasty balloon catheter containing an injection lumen (3mm x 10mm
Sprinter OTW balloon catheter, Medtronic) was positioned in the lower portion of the left
anterior descending artery (LAD; as defined as 1cm below the First Diagonal). The LAD
was occluded by balloon inflation (12 ATM balloon inflation pressure, Everest 30
Disposable inflation device, Medtronic) and maintained for 90 minutes.
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Prior to the initiation of the procedure, the pigs were randomly assigned, in a
blinded fashion to the following groups: IR induction only (IR-only; n=8), IR-gel only (IRgel; n=4), or IR-gel containing SD7300 (IR-gel/7300; n=7). The balloon was then
deflated and the catheter system disengaged and removed. The femoral artery was
ligated and the incision closed. A transdermal fentanyl patch was placed for 3 days for
post-operative analgesia.

5.2.5. HYDROGEL INJECTIONS INTO PIGS
To perform the MI injections, the pigs randomized to this protocol were returned
to the cardiac surgical laboratory 3-5 days after MI, and anesthesia performed as
described previously [ref]. A 1.5 cm incision was made at the right anterior sternal-costal
cartilage junction, just superior to the xiphoid process. A pediatric Finochietto retractor
was placed and the anterior aspect of the LV containing the MI region exposed. The
pericardium was incised, and the MI region constituting a ~3X3 cm area was visualized
and the basal and apical borders of the MI identified.
A preloaded syringe containing the hydrogel was connected to a 2”, 24 gauge
needle (BD), and 9 injections of 100 uL volume each were placed in a equidistant
diamond shape pattern within the MI region at a depth of 5 mm, forming clear solid gel
pockets below the epicardial surface of the MI. At the conclusion of the injections, the
incisions were closed without irrigation, and the total procedural time was 30±5 min.
Only transient, non-sustained arrhythmias were encountered during the actual injections,
and no other intra/post-operative complications were encountered.
To visualize hydrogel distribution, cardiac tissue (n=1) was explanted
immediately after injections and imaged on a 9.4T MRI scanner (Siemens). A T2weighted turbo spin echo with the following parameters was used to acquire segments
for 3D reconstruction: matrix size 320x256x65, voxel size = 0.3125x0.3125x1.0 mm3,
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repetition time = 1128 ms, echo time = 71 ms, 4 signal averages. Hydrogel pockets were
visualized using 3D reconstructions of myocardial segments in ITK-SNAP2.
To track small molecule release in vivo, IR800 dye (Licore) was used as a
representative small molecule and loaded into guest-host hydrogels at a concentration of
1 mg/mL hydrogel and injected into MI regions as described above. Sacrifice (n=1)
occurred 2 days after injection, at which point the myocardium was sectioned into 0.25
cm thick, short-axis sections and imaged using an IVIS transdermal imaging system and
presented as overlay images with bright field images of the myocardial section.

5.2.6. FUNCTIONAL ANALYSIS
Baseline echocardiography prior to IR induction, as well as 14 and 28 days postIR were performed. To accomplish this, animals were sedated (diazepam, 200mg-PO,
Barr Laboratories, Pomona, NY) and echocardiography performed (GE Vivid E9
Dimension Ultrasound System: M5S 1.5-4.6 MHz active matrix array sector transducer
probe) in order to measure LV volumes, left atrial (LA) area, posterior LV free wall
thickness, and ejection fraction. In addition, mitral valve inflow velocities and tissue
Doppler were used to compute an estimate of pulmonary capillary wedge pressure.
Digital loops of the two-dimensional echocardiography for the LV long and mid-papillary
short axis (acquired at 40 Hz) were digitally acquired for analysis (EchoPac, Vingmed,
General Electric).

5.2.7. TISSUE ANALYSIS
28 days post-IR and after echocardiography, pigs were anesthetized (5%
isoflurane) and the LV region containing the MI and remote tissue (LV posterior wall
encompassing the posterior descending artery) were harvested. LV sections were then
subjected to histochemical staining for MI size. Briefly, 0.25 cm thick sections of the
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myocardium were immersed in triphenyl tetrazolium chloride (TTC) solution for 20 min.
Sections were imaged and quantified using ImageJ. Tissue was also stained for collagen
content using a picosirius red staining kit. Sections from the MI region were taken for
subsequent RNA isolation (RNALater, Qiagen). An additional group of pigs (n=6) of
identical age and weight were included in this terminal study protocol in order to obtain
referent normal LV myocardium for comparative analysis.
RNA was extracted from the LV samples (RNeasy Fibrous Tissue Mini Kit, Qiagen)
and the quality and quantity of the extracted RNA determined (Experion Automated
Electrophoresis System; Bio-Rad Laboratories, Hercules, CA). The RNA was reverse
transcribed (iScript cDNA Synthesis Kit; Bio-Rad, Hercules, CA), and pig specific
primer/probe arrays for apoptosis and inflammation (RT2 Profiler PCR Custom Array,
PASS-0122 and CAPS11182, respectively, Qiagen) were completed. The reaction was
performed (RT2 SYBR Green@qPCR Mastermix, Qiagen) and quantified by real time
(CFX96 real-time PCR detection system, Bio-Rad, Hercules, CA). The real time PCR
fluorescence signal was converted to cycle times (Ct) normalized to GAPDH (ΔCt
method). All PCR assays were performed in duplicate.

5.2.8. STATISTICAL ANALYSIS
Injection force (n=3), SD-7300 release (n=4), and MMP activity (n=4) are
presented as mean and standard deviations. For functional studies, pigs were separated
into three treatment groups, MI (n=8), MI/Gel (n=4), and MI/Gel/SD7300 (n=7).
Functional data is reported as mean and standard error of the mean. Significance was
determined using a two-way ANOVA followed by pair-wise comparisons using the least
significant difference post hoc study. For change from baseline data, a t-test was
performed using a null hypothesis of a zero mean value. For MI size, PCR, and collagen
staining data, a one-way ANOVA was performed and pairwise comparisons were
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performed by an adjusted t-test. All analyses were performed with SPSS software
(version 24.0, SPSS Inc) and a p-value of < 0.05 was considered statistically significant.

5.3. RESULTS AND DISCUSSION
This study showcases a biomaterials approach to localize the delivery of a small
molecule MMP inhibitor. The development of MMP inhibitors for a variety of conditions
has been hampered by the induction of musculoskeletal syndrome as a result of offtarget action when the inhibitor is delivered systemically.

20,21

Thus, while molecules

such as SD7300 have been shown to be efficacious in their treatment of disease, their
utility has been limited in cases of MI, due to limited appropriate delivery mechanisms.
Here, an injectable hydrogel was developed that could be injected into a tissue to locally
release an MMP inhibitor.

5.3.1. MATERIAL DEVELOPMENT AND CHARACTERIZATION
Towards the hydrogel design, we build on our previous work in developing shearthinning hyaluronic acid (HA) hydrogels, that assemble from non-covalent guest-host
crosslinks between β-cyclodextrin and adamantane, allowing them to be injectable into
tissues (Figure 5.1a,b).25,26,32 In addition to adamantane, β-cyclodextrin has been shown
to have affinity for a wide range of small molecules, and is frequently used in the
pharmaceutical industry to solubilize and stabilize small molecules.33,34 Thus, we
engineered an appropriate interaction for SD7300 sustained release where the molecule
binds to β-cyclodextrin for retention and controlled release (Figure 5.1c).
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Figure 5.1. Schematic for hydrogel injection and SD-7300 release from guest-host
hydrogels. (a) Guest-host hydrogels are formed through self-assembly between
cyclodextrin (red) and adamantane (green) and loaded into syringes as a single
component. Upon application of shear via the syringe plunger, guest-host bonds
dissociate and material flows in a fluid-like state. Upon deposition, guest-host bonds
reassemble and the material behaves as a solid hydrogel. (b) Image of injection of
guest-host hydrogel onto a dry surface. (c) Cyclodextrin and SD-7300 (blue) interact
through reversible interactions at the hydrophobic core of cyclodextrin. Hydrogel
formulations containing excess cyclodextrin moieties relative to adamantane provide
binding sites for SD-7300. Affinity for the hydrogel backbone controls retention and
sustained release from the hydrogel over time.
Cyclodextrin modified HA (CD-HA) was synthesized by aminating β-cyclodextrin
and subsequently coupling this to HA via amidation so that 35% of repeat units on HA
were modified with CD (Figure 5.2a). Adamantane modified HA (Ad-HA) was
synthesized via esterification of HA with 1-ademantane acetic acid so that 25% of repeat
units on HA were modified with adamantane (Figure 5.2b). Hydrogels were rapidly
formed through the simple mixing of solutions of purified CD-HA and Ad-HA dissolved in
PBS.

We have previously shown that these materials possess unique mechanical

properties that allow for shear-thinning and self-assembly.32 Furthermore, these
hydrogels possess tunable mechanics based on the relative modification of HA
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macromers and injection into the myocardium can indeed provide functional benefits due
to tissue bulking effects.26 Finally, we have previously used this hydrogel system for cell
and drug delivery. 24,33
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Figure 5.2. 1H NMR spectra for modified hyaluronic acid. (a) NMR spectra for 35%
functionalized CD-HA and (b) NMR spectra for 25% functionalized Ad-HA.
Towards the design of hydrogels for clinical application, various features are
important, including injectability and controlled release. A variety of parameters can be
modulated to alter such properties and here, we explored the tuning of the ratio of
CD:Ad groups (1:1, 2:1, 3:1) in hydrogels with the same polymer concentration (6 wt%).
We observed that all hydrogels were viscoelastic and that hydrogels with the 1:1 ratio
maintained the highest level of mechanical properties (storage modulus) as determined
by frequency sweeps (Figure 5.3a), while increasing this ratio led to a drop in
mechanical properties. This is likely due to the mis-match in the guest-host groups,
which alters the number of effective crosslinks within the network. To probe the shearthinning behavior of the hydrogels, we conducted a shear rate sweep. Increasing the
CD:Ad ratio led to a more rapid decrease in viscosity in response to shear, suggesting
better shear-thinning behavior (Figure 5.3b). The greater mis-match in the guest-host
groups likely facilitated easier failure of the network under shear forces, due to lower
crosslinking.
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Because a formulation with a balance of mechanical properties for stability and
shear-thinning behavior for injectability is necessary, as well as an excess of
cyclodextrin to bind to encapsulated drugs, we selected the 2:1 formulation to proceed
with future studies. To directly evaluate injectability, we measured the injection force of
the 2:1 formulation under several different flow rates from a 1 mL syringe through a 21G
needle. We observed low injection forces across these injection rates (<50N)(Figure 5.3
c), which are comparable to clinically used hyaluronic acid dermal fillers.35
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Figure 5.3. Mechanical testing of various guest-host hydrogel formulations. (a)
Representative frequency sweeps (conducted at 1% strain between 0.01 Hz and 100 Hz
using a cone and plate geometry) of guest-host hydrogel formulations containing 1:1,
2:1, and 3:1 molar ratios of cyclodextrin to adamantane. Increasing cyclodextrin to
adamantane ratio corresponded to a decrease in mechanical properties for these
formulations. (b) Continuous flow studies (conducted between 1 and 10 Hz) of
representative samples of various guest-host hydrogel formulations. All materials
displayed shear-thinning behavior, with more rapid shear-thinning occurring in
formulations containing higher cyclodextrin to adamantane ratios. (c) Injection force data
at various rates of injection for 2:1 guest-host gel formulation. Bars represent average
and standard deviation of n = 3 separate runs.
5.3.2. DRUG RELEASE AND ACTIVITY
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Hydrogels formed from the 2:1 formulation were loaded with SD7300 at a final
concentration of 0.5mg/mL. The SD7300 release was sustained over 3 weeks with a
decrease in the release rate over time (Figure 5.4a). This sustained release is a result of
inclusion of the small-molecule binding cyclodextrin in the hydrogel formulation, which
was presented in excess of adamantane. In addition to directly measuring SD7300
release, the bioactivity of released SD7300 was measured using an in vitro estimate of
MMP-2 inhibitory activity (Figure 5.4b). At all time-points during release, we observed
almost complete inhibition of MMP-2 activity, suggesting that this formulation is highly
bioactive during the first month of use (Figure 5.4c).
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Figure 5.4. SD-7300 release from guest-host hydrogels and associated MMP-2
inhibitory activity. (a) SD7300 release profile from guest-host hydrogels showing
sustained release for approximately three weeks. (b) Schematic of fluorogenic MMP-2
activity assay. A fluorogenic peptide, when cleaved in the presence of MMP-2,
generates a fluorescent signal. The kinetics of this generation can be correlated with
MMP activity, and are decreased through MMP inhibition by SD7300. (c) MMP-2 activity
associated with release time points obtained during SD7300 release study. Activity was
negligible for all time points during the release assay.
Inclusion of cyclodextrin as a binding component for small molecules was shown to
be a successful approach for the sustained release of SD7300. Cyclodextrin is
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frequently used in numerous pharmaceutical formulations and is an FDA GRAS
molecule, lending translational merit to this approach for materials design. Because of
the widespread use of cyclodextrin in pharmaceutical formulations, this approach could
be broadly applicable for a number of small molecules requiring localized delivery in
broad applications (e.g. chemotherapeutics). The profile of drug release and activity
appropriately matches the acute phase of MI. Administration of MMP inhibition during
this time frame has been shown to be successful in providing attenuation of LV
remodeling, both in systemic and local administration of inhibitors.23,30,36 By inhibiting
matrix degradation during this early phase, the mechanical strength of the myocardium
can be maintained, leading to improved ventricular geometry and function.

5.3.3. MI INDUCTION AND LOCAL HYDROGEL INJECTION
MI was induced in mature Yorkshire pigs using a catheter balloon occlusion of
the left anterior descending artery for 90 minutes, then removal of the occlusion to allow
for reperfusion. Animals were returned for injection ~4 days after induction of MI, and
hydrogels were injected via a minimally invasive epicardial approach. Hydrogels were
subsequently injected across 9 injections of 100uL in a 3x3 array pattern within the
infarcted LAD region (Figure 5.5a,b). The injections left small pockets of transparent
hydrogel spaced throughout the infarcted myocardium. Heart tissue was explanted after
injection and imaged using MRI to evaluate the presence of hydrogel within the tissue.
Sample short-axis and long axis views show the presence of hydrogel within the
infarcted myocardial wall (Figure 5.5c,d). After 3D reconstruction, we observed that
these injection sites contain distinct depots of material within the tissue, suggesting
retention of the material through injection with this method (Figure 5.5e).
Additionally, we evaluated our material for the ability to localize a small molecule
to the myocardium. We loaded hydrogels with IR800 as a model small molecule tracker
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that could be detected using near-IR fluorescence imaging and tracked its release over
time (Figure 5.6a). Injections were performed post-infarction, and heart tissue was
explanted and sectioned into 0.25 cm thick sections 48 hours after hydrogel injection
and imaged using an IVIS transdermal imaging system. We observed localization of
fluorescent signal to infarcted myocardium, indicating successful localization of payload
to the areas of injection in the heart (Figure 5.6 b).

b

a

c

d

e

Figure 5.5. Injection of 2:1 guest-host hydrogel formulation into porcine
myocardium. Guest-host hydrogel was injected in a 3x3 array in the infarct region of the
myocardial wall using an epicardal injection, accessed via a mini-thoracotamy. (b) Image
of heart after hydrogel injections. (c) MRI long axis view of hydrogel injection sites in
explanted porcine myocardium immediately after injection. (d) MRI short axis view of
hydrogel injection sites in explanted porcine myocardium after injection. (e) 3D
reconstruction of hydrogel injection sites in explanted porcine myocardium.
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Figure 5.6. Release of near IR dye in vitro and in vivo. (a) In vitro release profiles of
IR 800 from 2:1 guest-host hydrogels. IR 800 released over approximately 1 week from
guest-host hydrogels. (b) Near IR fluorescent imaging of porcine myocardial sections
showing IR 800 intensity 48 h after injection. IR 800 was localized to the infarcted region
of the myocardium, suggesting minimal off target delivery of small molecules.

Small molecule MMP inhibitors have had limited success clinically in large part due
to their inability to be administered systemically without off target effects.20-22 Generally, it
is hypothesized that the broad musculoskeletal syndrome that has come to be
associated with systemic administration of these drugs is a result of the disruption of
normal matrix turnover in healthy sites of the body. While steps have been made to
address this by targeting specific subsets of MMPs through altering molecule design,
this has largely been inefficient in providing a means to attenuate these off-target
effects.37 Using near-IR imaging and near-IR payloads, we have shown the ability for our
materials to localize small molecules to injection sites in the infarcted myocardium. This
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allows for direct mitigation of off-target toxicity through localization of SD7300 to only the
diseased areas of the heart.

5.3.4. LV GEOMETRY AND CARDIAC FUNCTION
After confirmation of successful material and small molecule retention within the
infarcted myocardium, we explored the ability of SD7300 loaded hydrogels to promote
functional improvement after delivery. We evaluated three treatment groups, MI with
saline injections (n=8), MI with delayed hydrogel injections (n=4), and MI with delayed
SD7300

loaded

hydrogel

injections

(n=7).

Animals

were

evaluated

using

echocardiography at 14 and 28 days after infarction to determine ventricular geometry
and filling metrics (Figure 5.7).

Infarction

d0

Injection

d 3-5

Outcomes
• Echocardiography

d 14

Outcomes
• Echocardiography
• Histology

d 28

Figure 5.7. Schematic representation of animal model for functional studies.
Infarction was generated at day 0 using an ischemia-reperfusion injury, followed by a
return for material injection at day 3-5. Echocardiography was taken at d 14 and d 28, as
well as histologic and gene array analysis at d 28.
Treatment with MI/Gel/SD7300 shows significant decrease in left atrial (LA) area,
pulmonary capillary wedge pressure (PCWP), E/A ratio, and a significant increase in E’
at both 14 d and 28 d time points as compared to saline controls, while gel only
treatment showed no statistical significance, but a trend for improvement in these
metrics over saline alone (Figure 5.8a-d). These data suggest that that gel./SD7300
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combination treatment provided increased benefit over gel alone treatment and was
important for improving diastolic function in the heart.
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Figure 5.8. Indices of filling for longitudinal functional study of SD-7300 loaded
hydrogels. (a) Left atrial (LA) area, (b) pulmonary capillary wedge pressure (PCWP), (c)
E/A ratio, a ratio of peak blood flow during early diastole to peak blood flow in late
diastole and a metric of left ventricular function, and (d) E’ of animal groups treated with
MI only (blue, n= 8), MI/Gel (red, n =4) and MI/Gel/SD7300 (green, n= 7) at baseline and
14 and 28 days after MI. At day 14, animals treated with MI/Gel/SD7300 had significantly
lower LA Areas, lower PCWP, and higher E’ than animals receiving MI alone. At day 28,
animals treated with MI/Gel/SD7300 had significantly lower LA Areas, lower PCWP,
lower E/A ratios, and higher E’ than animals receiving MI alone. Dashed line represents
the average of baseline values for all animals used in the study. Statistics were
determined using two-way ANOVA, with + representing p<0.05 in comparison to MI
group and # representing p<0.05 in comparison to MI/Gel group.
Analysis of ventricular geometry shows significant increase in ejection fraction at
14 d and 28 d time points for the MI/Gel/SD7300 treatment as compared to the saline
treatment, with a non-significant trend for improvement over the gel alone treatment
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(Figure 5.9a). Similarly, MI/Gel/SD7300 treatment showed significantly lower LV end
diastolic and systolic volumes at both 14 and 28 days, with a non-significant trend for a
decrease over the gel alone therapy (Figure 5.9b,c). Finally, while no significant trends
were observed in LV pulmonary wedge thickness at end diastole, MI/Gel/SD7300
provided significantly higher LV septal thicknesses at end diastole as compared to saline
controls (Figure 5.9d,e). These trends are also reflected in an analysis of these
parameters’ percent change from baseline values (Figure 5.10). Taken together, these
data suggest that Gel/SD7300 combination treatment provided increased benefit over
gel alone treatment in improving cardiac function and attenuating LV dilation.
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Figure 5.9. LV Geometry and Function. (a) Ejection fraction (EF), (b) LV end diastolic
volume (EDV), (c) LV end systolic volume (ESV), (d) LV pulmonary wall thickness
(LVPWThd) at end diastole, and (e) LV septal thickness at end diastole (LVSThD) for
animals treated with MI (blue, n=8), MI/Gel (red, n=4), and MI/Gel/SD7300 (green, n=7)
at baseline and 14 and 28 days after MI. Animals in the MI/Gel/SD7300 group had
significantly higher EF, lower LVEDV, lower LVESV, and higher LVSThd at 14 and 28
days as compared to the MI group. Dashed line represents the average of baseline
values for all animals used in the study. Statistics were determined using one-way
ANOVA, with + representing p<0.05 in comparison to MI group and # representing
p<0.05 in comparison to MI/Gel group.
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Figure 5.10. Percent change in LV Geometry and Function. Percent change in (a)
ejection fraction (EF), (b) LV end diastolic volume (EDV), (c) LV end systolic volume
(ESV), (d) LV pulmonary wall thickness (LVPWThd) at end diastole, and (e) LV septal
thickness at end diastole (LVSThD) for animals treated with MI (blue, n=8), MI/Gel (red,
n=4), and MI/Gel/SD7300 (green, n=7) at baseline and 14 and 28 days after MI. Animals
in the MI/Gel/SD7300 group had significantly lower decreases in EF, lower increases in
LVEDV, lower increases in LVESV, and higher increases LVSThd at 14 and 28 days as
compared to the MI group. Statistics were determined using one-way ANOVA, with +
representing p<0.05 in comparison to MI group and # representing p<0.05 in comparison
to MI/Gel group.
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Both the generation of infarction and the timing of biomaterial delivery are important
factors when considering the design of MI animal models. It is important to consider the
generation of clinically relevant infarcts when evaluating new potential therapies. In this
study, we utilized a balloon catheter approach to provide an ischemia/reperfusion injury
to the myocardium, as opposed to traditional methods of ligation. Importantly, as the
majority of patients undergoing an infarction will receive intervention to provide
reperfusion of the infarcted tissue, this model recreates the scenario of reperfused,
ischemic tissue in the myocardium. Furthermore, Yoshizumi et al provided evidence
suggesting that the timing of biomaterial delivery after an infarct plays a critical role in
determining the efficacy of improvement in tissue and functional outcomes.38 It is also
important to consider timing from a translational standpoint, as biomaterials-based
interventions would likely not be administered for at least 24 hours or longer after
diagnostic and logistical considerations. A significant impact of this work lies in the fact
that these materials have been evaluated in an ischemia-reperfusion model of MI with
delayed biomaterial injections. Functional data indicates that these materials are
effective mechanically and bioactively at delayed time points, suggesting their utility in
clinically relevant infarcts and time frames.

5.3.5. TISSUE ANALYSIS
At 28 days, hearts were harvested from animals and frozen for subsequent
analysis. First, to assess infarct size and expansion, hearts were sectioned into 4 cm
thick sections and stained with TTC to assess the metabolically active/inactive regions of
the myocardium (i.e. healthy/infarcted tissue). Analysis of these sections showed that
gel/SD7300 treatment provided a significant decrease in absolute MI areas, percentage
MI of total LV area, and percentage MI of area at risk, as well as a generally nonsignificant trend for improvement with gel alone treatment (Figure 5.11). These data
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suggest improved attenuation of infarct expansion by treatment with SD7300, although
some effect was observed with injection of hydrogel alone.
To further probe mechanistic effects of localized inhibitor treatment, we
conducted PCR arrays assessing cytokines and fibroblast gene profiles in the infarcted
region of the myocardium (Table 5.1 and Table 5.2). Almost all genes investigated in this
study were significantly different than healthy referent controls. This indicates the
significant underlying biological changes that occur in fibroblast and cytokine expression
after the induction of MI. Looking closer at gene expression related to ECM production,
we observed non-significant decreases in Col1A1 and Col6A expression in the
myocardium in animals treated with Gel/SD7300 as compared to gel alone and MI
controls (Figure 5.12a,b). Furthermore, collagen presence in the myocardium was
measured using picrosirus red staining, and we observed a significant decrease in
collagen in animals treated with Gel/SD7300 as compared to gel alone and saline
controls (Figure 5.12c). Taken together, these data suggest that Gel/SD7300 treatment
provides direct influence on cellular phenotype and gene expression in the myocardium,
ultimately contributing to a decreased fibrotic response.
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Figure 5.11. TTC staining of sectioned myocardium. (a) Infarct area, (b) percentage
infarct of total LV area, and (c) percentage infarct of area at risk for animals treated with
MI (blue, n=8), MI/Gel (red, n=4), and MI/Gel/SD7300 (green, n=7) at 28 days. Animals
treated with MI/Gel/SD7300 had significantly lower infarct size, and percentage infarct of
LV and area at risk. Statistics were determined using one-way ANOVA, with +
representing p<0.05 in comparison to MI group and # representing p<0.05 in comparison
to MI/Gel group.
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Table 5.1 Cytokine PCR Array Results. A one-way ANOVA test was used to determine
statistical significance against a referent control (RC) (p<0.05, *) or against MI only
(p<0.05, +)

Gene

RC
Detecte
dn

MI Only

n

ACTA2

5

4.67±1.12
*

4

CCL2

5

2.55±1.07

6

CCL3L
1

3

CD44

5

CSF2

0

3.50±0.81
*
2.80±0.77
*
Detected#

IFNG

4

0.13±1.15

IL10

2

IL6

0

IL8

1

MMP8

1

MMP9

2

TNF

5

3.04±0.99
*
Detected#
2.63±0.85
*
1.95
8.98±2.05
*
0.64±1.42

MI/Gel

1

4.42±0.72
*
3.24±0.95
*
5.76±1.69
*
2.74±0.65
*
Detected#

4

0.60±1.18

6
6

4.39±1.69

3

4.08±1.80

5

0.71±0.80
8.76±1.91
*

2

1

3.07±1.34

4

1.33
7.21±2.15
*
3.49±0.98
*

5
1

5
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n

2

1

6

MI/Gel/
SD7300
3.93±1.23
*
3.42±1.10
*
5.30±0.12
*
2.65±0.86
*
Detected#
3.27±0.24
*
4.06±1.20
*
ND

4.47±0.57
*
Detected#

6

n
4
4
4
4
2
4
4

4

6
6
3
6
1
2
6
6

5
5

Table 5.2 Fibroblast PCR Array Results. A one-way ANOVA test was used to
determine statistical significance against a referent control (RC) (p<0.05, *) or against MI
only (p<0.05, +)
MI Only

n

MI/Gel

n

MI/Gel/SD7300

n

ACTA2

RC
Detected
n
5

4.67±1.12*

4

4.42±0.72*

4

3.93±1.23*

6

CCN2

5

5.23±0.46*

5

4.56±0.62*

4

4.67±0.87*

6

COL1A1

5

7.36±0.26*

5

7.02±0.73*

4

6.24±1.11*

6

COL6A

4

4.11±0.90*

5

3.71±1.07*

4

1.40±1.89

6

EDA FN

4

8.76±1.36*

6

7.76±0.92*

4

7.74±1.04*

6

ITGA3

3

4.28±1.17*

5

4.58±0.88*

4

3.58±0.91*

5

LOX

4

5.20±0.99*

6

5.64±0.49*

4

5.08±1.08*

6

MYH14

5

0.81±0.47*

6

1.08±0.27*

4

0.77±0.34

6

P311

4

2.71±0.46*

5

2.92±0.66*

4

2.55±0.81*

6

SPP1

4

7.61±1.49*

6

6.18±1.52*

4

6.28±1.16*

6

TGFB

5

3.93±0.70*

6

3.48±0.61*

4

3.12±0.81*

6

VIM

4

5.24±0.45*

5

4.38±0.48*

4

3.12±0.61*+

5

Gene
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Figure 5.12. Collagen PCR and picrosirius red staining. PCR gene array samples for
(a) Col6A and (b) Col1A1 and percentage of infarct containing collagen determined
through picrosirius red staining for animals treated with MI (blue, n=8), MI/Gel (red, n=4),
and MI/Gel/SD7300 (green, n=7) at 28 days. Animals treated with MI/Gel/SD7300 had a
trend for lower Col6A and Col1A1 gene expression that was carried forward to
significantly lower collagen percentages in the infarct. Statistics were determined using
one-way ANOVA, with + representing p<0.05 in comparison to MI group and #
representing p<0.05 in comparison to MI/Gel group.
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5.4 CONCLUSIONS
This study has shown the development of an injectable, self-assembled hydrogel
formulation for the delivery of the small molecule MMP inhibitor SD-7300. These
materials provided month-long sustained release and activity of SD-7300 in vitro, and
were able to localize small molecules to the myocardium in vivo. Hydrogels delivering
SD-7300 were delivered in an ischemia-reperfusion, delayed injection model of MI and
provided improved functional and structural benefit over hydrogel alone and saline
controls. Finally, we observed that mechanistically, these systems may be exerting their
effect on collagen production and regulation in the myocardium. Moving forward, these
materials have broad impact on MMP inhibition therapies, as they solve key problems
associated with systemic administration of these pharmacologics through local and
sustained delivery.
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Chapter 6
INJECTABLE GRANULAR HYDROGELS WITH MULTIFUNCTIONAL PROPERTIES
FOR BIOMEDICAL APPLICATIONS

Adapted from:
Mealy JE, Chung JJ, Jeong HH, Issadore D, Lee D, Atluri P, Burdick JA. Injectable
Granular Hydrogels with Multifunctional Properties for Biomedical Applications.
Advanced Materials. 2018 May;30(20):1705912.

6.1. INTRODUCTION
Biomaterials are being developed as useful therapeutic modalities for a wide
range of applications, including for the delivery of cells and molecules (e.g.
pharmacologics, cytokines, growth factors), as cell scaffolds for tissue engineering and
regenerative medicine, and for mechanical support and tissue bulking.1,2 Many biological
contexts such as development, inflammation, and tissue repair are quite complex and
would benefit from multiplexed functionality (e.g. multiple independent drug delivery
rates, multi-modal degradation behavior, hierarchical mechanical properties) in
therapeutic design.
To address this, biomaterials are now evolving beyond simple static and uniform
materials to incorporate and harness this complexity through advanced material design.
As examples, approaches to introduce multiplexed functionality in molecule delivery
have included composite embedding techniques, layer by layer design, or simple coencapsulation of multiple factors within a single material.3-6 Furthermore, techniques
such as photolithography and 3D printing are emerging to improve the spatial design of

134	
  

multifunctional materials.7,8 Despite these advances, there is a disparity between
creating highly complex materials and doing so in a manner that is broadly amenable to
clinical translation, such as with the use of injectable materials.
Injectable materials – commonly hydrogels - can be introduced into tissues via
percutaneous procedures using syringes and catheters and have been used in
numerous biomedical applications.9-14 Traditionally, these materials are isotropic and
homogeneous, frequently designed with a single set of input parameters governing the
material function. Self-assembled hydrogels are a subset of these materials, where
crosslinking chemistry is derived from non-covalent interactions including hydrophobic,
ionic, and guest-host binding.15 These materials are often both shear-thinning and selfhealing, which permits ease of injection and then stabilization upon reaching the
injection site. For example, we developed a hydrogel system based on the guest-host
assembly of polymers modified with cyclodextrin and adamantane that exhibited these
properties and could be injected into tissues.16-18 Thus, there is a need for materials that
are injectable and can be engineered to meet the complex demands of tissue repair.
To meet this challenge, we developed a granular hydrogel system, based on the
interactions of modular microgel components via guest-host interactions. Particulate
assemblies are commonly designed through the association of nano- and micro-scale
components and have recently found utility as cell culture platforms, wound healing aids,
and drug delivery systems.4,19-22 Guest-host interactions have not been previously used
for the formation of granular systems and our design provides a high level of control over
the hydrogel properties through the combination of microgels, including controlled drug
delivery and porosity for cell invasion. Specifically, we fabricated crosslinked hyaluronic
acid (HA) microgels with modular intra-particle covalent crosslinking that were formed
into an injectable granular hydrogel through the use of cyclodextrin and adamantane
guest-host inter-particle crosslinking. Here, we explored these materials for application in
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the treatment of cardiac tissue after injuring, by introducing temporally controlled porosity
and drug delivery.

6.2. METHODS
6.2.1. MATERIAL SYNTHESIS
All materials were purchased from Sigma unless otherwise noted. Sodium
hyaluronate (HA, 75 kDa, Lifecore) was first converted to a tetrabutylammonium salt
(HA-TBA) through the use of an ion exchange resin (Dowex50Wx4) to facilitate further
modification. Briefly, HA was dissolved in aqueous solution and mixed with resin for 4 h,
after which the resulting solution was neutralized with tetrabutylammonium hydroxide.
The resulting aqueous solution was frozen and lyophilized to yield dried HA-TBA.

1

H-

NMR (360 MHz, Bruker) was used to characterize the final product.
CD-HA was synthesized using previously described protocols.17 Briefly, an
aminated β-cyclodextrin was coupled to HA-TBA in a solution of dimethyl sulfoxide
(DMSO) containing (benzotriazol-1-ylozy)tris(dimethylamino)phosphonium catalyst and
allowed to proceed for 3h at room temperature. The resulting macromer was purified
through precipitation in cold acetone, followed by dialysis against water for 2 weeks. The
CD-HA solution was then frozen, lyophilized, and characterized via 1H-NMR to yield
~25% modified CD-HA (Figure 6.1a).
Ad-NorHA was synthesized using a one-pot esterification reaction. HA-TBA, 1adamantane acetic acid (TCI America) and 5-norbornene-2-carboxylic acid were
dissolved in DMSO containing 4-methylaminopyridine and di-tertbutyl dicarbonate
catalysts. The reaction was allowed to proceed for 20 h at 45 °C. The resulting product
was purified via precipitation in cold acetone, and dialysis against water for two weeks.
Ad-NorHA was then frozen, lyophilized, and characterized via 1H-NMR to yield ~40%
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norbornene and ~40% adamantane modified HA (Figure 6.1b). NorHA was synthesized
in a similar protocol, excluding the adamantane reactants, to yield ~35% norbornene
modified

HA

(Figure

6.1c).

23

b

a

c

Figure 6.1. NMR spectra for modified HA macromers. 1H-NMR (360MHz, D2O) of
modified hyaluronic acid polymers. (a) NMR spectrum for CD-HA with peaks from δ ~
1.35 – 1.85 ppm used for determination of relative modification of cyclodextrin. (b) NMR
spectrum for AdNorHA with peaks at δ ~ 6.3 ppm and δ ~ 6.0 ppm used for
determination of relative modification of norbornene and peaks at δ ~ 1.6 ppm and δ ~
1.4 ppm used for determination of relative modification of adamantane. (c) NMR
spectrum for NorHA with integrated peaks at δ ~ 6.3 ppm and δ ~ 6.0 ppm used for
determination of relative modification of norbornene.
6.2.2. PEPTIDE SYNTHESIS
Peptides were synthesized via fluorenylmethyloxycarbonyl (FMOC) solid phase
peptide

synthesis

and

glycanol

2-chlorotrityl

substrate

(GCKK-RHO,

GCNSVPMSMRGGSNCG) or a 1,6 diaminohexane trityl resin (GCKK-FITC). Peptides
were cleaved from the resin in a mixture of trifluoroacetic acid, triisopropylsilane, and
water (95:2.5:2.5) and then purified by precipitation in cold diethyl ether. Peptides were
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then dissolved in water, frozen, and lyophilized. Peptides were then characterized via
MALDI-TOF spectroscopy (Multiflex, Bruker).

6.2.3. DEVICE MANUFACTURE
As described previously, a three-dimensional monolithic elastomer device (3D
MED) was used for scale-up of liquid droplets.24 A 3D MED was fabricated with poly
dimethyl siloxane using a double-sided imprinting method with a hard and soft master.
The fabrication of hard and soft master was formed by conventional photo- and softlithography.

6.2.4. MICROGEL SYNTHESIS
A dispersed phase consisting of 3 wt% aqueous macromer (Ad-NorHA, NorHA)
0.05 wt% I2959, thiol crosslinker, and payload (FITC-BSA, 70kDa RHO-Dextran)
pumped at 0.6 mL/h was focused into droplets using a dispersed phase of hexadecane
containing 2 wt% Span80 flowed at 3.5 mL/h. Thiolated crosslinkers were included to
consume 15% of norbornene units in the case of stable (DTT) and to consume 7.5% of
norbornene groups in the case of cleavable microgels (GCNSVPMSMRGGSNCG), due
to increased solution viscosity caused by charge interactions from the peptide. Droplets
were collected and cured off chip using 365 nm UV light (Omnicure S1500, Excelitas
Technologies) at approximately 10mW cm-2.
For covalently-labeled materials, thiolated fluorophores (GCKK-FITC and GCKKRHO) were included in the dispersed phase and coupled to microgels via thiolnorbornene photochemistry during curing. Crosslinked microgels were then purified by
precipitation in cold acetone, followed by washing with isopropyl alcohol, then
subsequent drying under vacuum to yield dried microgel product. Microgels were
characterized using fluorescent and confocal microscopy, and microgel size was
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calculated using ImageJ particle tracker on an analysis of ~50 microgels. To prepare
granular hydrogels, microgels and CD-HA were dissolved at 10 wt% in phosphate
buffered saline. For mixed microgels, the dried microgel powders were mixed prior to
hydration.

6.2.5. IN VITRO MATERIAL CHARACTERIZATION
Granular hydrogels were imaged using a Leica TCSP5 confocal microscope and
3D reconstructions were rendered using ImageJ. Hydrogel mechanics were assessed
using a stress-controlled rheometer (AR2000, TA) fitted with a 20 mm diameter flat plate
geometry and a 300 µm gap height. Oscillatory frequency sweeps were conducted
ranging from 0.01 to 100 Hz, while cyclic strain experiments were conducted by cycling
between 1% and 500% strain at 1 Hz. Drug release was assessed using custom
designed erosion cells in which 30 µL of gel was placed in a 4.3 mm diameter
depression in a 1.6 cm diameter supernatant chamber. The chamber was filled with 1
mL PBS supplemented with 1 mM CaCl2 containing either 200 U/mL Type IV
collagenase or 0 U/mL collagenase. Releaseate was collected and analyzed for FITCBSA release at λex = 490, λem = 525 or for RHO-Dextran release at λex = 544, λem = 576.
Material degradation was assessed using a colorimetric uronic acid assay, as performed
previously.[18]

6.2.6.

IN

VIVO

MYOCARDIAL

INFARCTION

STUDIES

OF

MATERIAL

DEGRADATION
The in vivo studies included an infarction and non-infarcted group to investigate
differential degradation patterns under these two conditions. Using an established
protocol of myocardial infarction (MI) in a rat model, 8-9 week old male Wistar rats were
anesthetized, mechanically ventilated and underwent permanent ligation of the left
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anterior descending artery to produce a 30-40% infarction of the left ventricle, confirmed
by blanching of the myocardium in the appropriate distribution. Using a 27 G needle on a
0.5 mL syringe, labeled granular hydrogel containing equal masses of cleavable and
stable microgels was delivered directly into the infarcted myocardium, as five discrete 10
µL injections. Care was taken to avoid intraventricular delivery of the hydrogel and the
formation of visible hydrogel pockets confirmed containment within the myocardial
tissue. The no MI group received the same 5 x 10 µL injections of gel into healthy
myocardium corresponding to the infarcted region of the MI group. Due to the nature of
the procedure, the surgeon was not blinded, although the treatment groups were
randomly assigned. At pre-assigned timepoints of 1, 2, and 3 weeks, the rats were
sacrificed and the hearts were explanted, flushed with PBS and preserved in OCT at 80°C for histologic analysis. 10 µm transverse sections were taken through the area of
infarct. Sections were stained using hematoxylin and eosin (Sigma) and DAPI (Thermo
Fisher) staining. Sections were stained using DAPI and hematoxylin and eosin staining.

6.2.7. IMAGE ANALYSIS FROM IN VIVO DEGRADATION STUDIES
Hearts from MI and non-MI groups (n=3) after 2 weeks were sectioned and three
sections per animal were analyzed. Injection site area was estimated by the minimum
region including all microgels (Figure 6.2a). For each section, red and green channel
images were split (Figure 6.2b) and thresholded with a minimum intensity of 20 and
maximum intensity of 255 to form a binary mask (Figure 6.2c). Masked areas were
computed using the “measure” function in ImageJ. Areas of cleavable and stable
microgels were then normalized to the total injection site area, to yield an area fraction:
𝑁𝑜𝑟𝑚𝑎𝑙𝑖𝑧𝑒𝑑 𝑀𝑖𝑐𝑟𝑜𝑔𝑒𝑙 𝐴𝑟𝑒𝑎= T𝑜𝑡𝑎𝑙 𝑀𝑖𝑐𝑟𝑜𝑔𝑒𝑙 𝐴𝑟𝑒𝑎/𝐼𝑛𝑗𝑒𝑐𝑡𝑖𝑜𝑛 𝑆𝑖𝑡𝑒 𝐴𝑟𝑒𝑎
Intensity density was calculated by summing the total pixel intensity in either the red or
green channel, then dividing by the estimated injection site area:
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𝑁𝑜𝑟𝑚𝑎𝑙𝑖𝑧𝑒𝑑  𝑀𝑖𝑐𝑟𝑜𝑔𝑒𝑙  𝐹𝑙𝑢𝑜𝑟𝑒𝑠𝑐𝑒𝑛𝑐𝑒 =   

𝑇𝑜𝑡𝑎𝑙  𝑀𝑖𝑐𝑟𝑜𝑔𝑒𝑙  𝐹𝑙𝑢𝑜𝑟𝑒𝑠𝑐𝑒𝑛𝑐𝑒
𝐼𝑛𝑗𝑒𝑐𝑡𝑖𝑜𝑛  𝑆𝑖𝑡𝑒  𝐴𝑟𝑒𝑎

Area fractions and intensity densities for each animal were determined, then averaged
for three biological replicates in each group.

a

b

c

Injection Site Area

Figure 6.2. Example image series from image analysis on in vivo studies. (a)
Composite image showing cleavable microgels (green), stable microgels (red), and cell
nuclei (blue), and the estimated injection site area (yellow). (b) Red channel image of
stable microgels. (c) Thresholded mask of (b) used for computing stable microgel areas
used in area fraction calculations.
6.2.8. IN VIVO FUNCTIONAL STUDIES
To investigate the potential of the granular hydrogel for the delivery of therapeutic
molecules, stromal-derived factor 1-alpha (SDF-1α) was encapsulated into the cleavable
microgel portion of the injectable hydrogel. Encapsulation was performed as above,
using DTT as the crosslinker. The release of SDF-1α from the hydrogel composite was
investigated as described above, using an ELISA for SDF-1α to quantify release over
time.
Using the previously described protocol, MI was generated in Wistar rats via
ligation of the left anterior descending artery accessed using a left lateral thoracotomy.
Animals were randomly assigned to three groups: PBS injections, granular hydrogels
without SDF-1α, and granular hydrogels containing SDF-1α encapsulated in cleavable
particles at approximately 0.33 µg/mg HA. Similar to degradation studies, materials were
injected into the border zone region through 5x10 µL, with a final SDF-1α content of
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approximately 1 µg per animal. Prior to tissue explant at 4 weeks, cardiac function was
determined using a 12-mm pressure-volume loop catheter (Millar).

6.2.9. IMMUNOHISTOCHEMISTRY
Using a cryostat, 10 µm tissue sections were obtained from explanted hearts that
had been washed in PBS, and frozen in OCT. For analysis of microvasculature, tissues
were stained with primary antibodies for isolectin, α-smooth muscle actin (α-SMAAF594, Abcam, 1:400), wheat germ agglutinin (WGA-AF647, 1:300), and DAPI (D1306
ThermoFisher Scientific, 1:1000).

Images were collected using a Leica DM5000b

fluorescent microscope with a DFC350 FX monochrome camera at 10x magnification.
Isolectin area and isolectin co-localized α-SMA area were quantified using ImageJ. At
least two images collected at the border zone were analyzed and averaged for each
biological replicate (n=3 for PBS, gel, and gel/SDF groups).
To determine the effect of granular systems on macrophage response, tissue
sections were stained for CD68 (MCA341GA, Bio-Rad, 1:300) and with goat anti-mouse
AF647 secondary antibody (ab150115, Abcam, 1:300) as well as DAPI to visualize
cellularization. Image analysis of CD68+ area fraction was conducted in ROIs at the
border zone, in the vicinity of (but not including) microgel injections, determined by the
absence of significant DAPI staining. Images were thresholded to form a binary mask,
which was used to determine CD68+ area for at least 4 images per biological replicate
(n=3 for each group). Finally, to determine the effect of SDF, cells were stained for the
SDF receptor, CXCR4 using with a goat anti-CXCR4 primary antibody (ab1670, Abcam,
1:300) and a FITC donkey anti-goat secondary antibody (Abcam 7121, 1:1000). Images
were thresholded to form a binary mask, over which particle counts were conducted to
determine CXCR4+ cells for each high powered field.
analyzed and averaged for each biological replicate.
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At least four images were

6.2.10. STATISTICAL ANALYSIS
Data is presented as mean ± standard deviation. Statistical analysis was
conducted using ANOVA and a post hoc Tukey’s Honestly Significant Difference test
(p<0.05, p<0.005) on mechanical time sweeps, and a two-tailed student t-test on
quantified tissue section data (p<0.05).

6.3. RESULTS AND DISCUSSION
A granular hydrogel system was developed that involved crosslinked hyaluronic
acid (HA) microgels with modular intra-particle covalent crosslinking that were formed
into an injectable granular hydrogel through the use of cyclodextrin and adamantane
guest-host inter-particle crosslinking (Figure 6.3a). These materials were evaluated for
modular, multiplexed functionality in vitro and in vivo, and then applied as a therapeutic
system in a rat model of MI.

6.3.1. MICROGEL AND GRANULAR HYDROGEL FABRICATION
To fabricate microgels, we used a novel poly dimethyl siloxane (PDMS)
microdevice to provide high throughput droplet generation (Figure 6.3b).24 Droplets
contained norbornene modified hyaluronic acid (Figure 6.3a) or adamantane and
norbornene modified hyaluronic acid (AdNor-HA, Figure 6.3a), di-thiol crosslinkers (e.g.,
dithiotritiol (DTT), peptides), and a photoinitator, as well as fluorescein isothiocyanate
(FITC) labeled bovine serum albumin (BSA) to image microgels. The droplets were
crosslinked using a photoinitiated thiol-ene reaction to form microgels having diameters
of 43 ± 10µm and 46 ± 12µm, depending on the crosslinker used (Figure 6.4). While
some size dispersity was observed, potentially due to the drying and hydration process,
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we were able to manufacture droplets at 0.6 mL of hydrogel precursor per hour through
the use of 8 parallel droplet generators on a single device. This enabling technology is
particularly useful when considering scale up of such systems for translation and this
design has used up to hundreds of parallel droplet generators on a single device,
processing solutions at rates as high as 1.5 L/h.24
In order to form and visualize the material microstructure, dry FITC-BSA loaded
microgels were reconstituted in phosphate buffered saline (PBS) and combined with
rhodamine (RHO) labeled cyclodextrin modified HA (CD-HA, Figure 6.3c). Gelation
occurred instantly upon mixing of these two components to form the granular hydrogel.
Confocal imaging of the hydrogel showed a clear “brick and mortar” structure, where
distinct regions of FITC labeled microgels were interconnected by a web of RHO labeled
CD-HA (Figure 6.3c). These images highlight the hierarchical structure of the material,
which can be exploited to introduce functionality.
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Figure 6.3. Guest-host granular hydrogel fabrication. (a) Schematic representation of
guest-host granular hydrogel formation via the mixing of crosslinked adamantane
(green) and norbornene (blue) modified hyaluronic acid (AdNor-HA) microgels and
cyclodextrin (red) modified HA (CD-HA). (b) Schematic representation of the microgel
fabrication process by which macromer droplets (containing AdNor-HA, di-thiol
crosslinker, photoinitiator) are formed using a high throughput microfluidic device and
stabilized through a photoinitiated thiol-ene reaction to form stable microgels that
averaged ~43 µm in diameter. Scale bars from left to right are 500, 100, and 100 µm. (c)
Confocal image (cross-sectional (left) and top (right) views) of a guest-host granular
hydrogel formed with rhodamine labeled CD-HA and fluorescein labeled microgels.
Scale bar = 200 µm.
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a

43 ± 10 µm

b

46 ± 12 µm

Figure 6.4. Size distributions of hydrated microgels. Sizing was assessed through
fluorescent imaging for (A) microgels crosslinked using DTT (n=55) and (B) microgels
crosslinked using an MMP cleavable peptide (n=49).
6.3.2. GRANULAR HYDROGEL MECHANICAL PROPERTIES
The mechanical properties of granular guest-host hydrogels were investigated
using stress controlled shear oscillatory rheology. A series of three formulations was
investigated: a “granular hydrogel” group containing 5wt% AdNorHA microgels
crosslinked with DTT and mixed with 5wt% CD-HA, a “microgel control” group containing
5wt% NorHA microgels crosslinked with DTT and mixed with 5wt% CD-HA (i.e. no
adamantane guest for inter-particle crosslinking), and a “polymer control” group
containing 5wt% AdNorHA microgels crosslinked with DTT and mixed with 5wt% HA (i.e.
no cyclodextrin host for inter-particle crosslinking) (Figure 6.5a). Across frequencies
ranging from 0.01 Hz to 100 Hz, the granular hydrogel group maintained the highest
mechanics of all three groups, with the microgel control group having an intermediate
level of mechanics, and the polymer control group having the lowest mechanics (Figure
6.5b). Furthermore, when 1 Hz and 10 Hz frequencies were probed in time sweeps, the
granular hydrogel was significantly higher (p<0.05) than either control system in both
storage and loss moduli. All groups, however, did behave rheologically as hydrogels (i.e.
G’ > G”), potentially as a result of dense microgel packing in all conditions (Figure 6.5c).
It is likely that the high mechanical properties observed in the granular hydrogel system
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are a result of the guest-host inter-particle crosslinking, while the intermediate
mechanics in the microgel control could be a result of promiscuous interactions between
cyclodextrin and unreacted norbornenes, as well as molecule hydrophobicity.25

b

a
Granular
Hydrogel
Microgel
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c
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Figure 6.5. Rheological properties of guest-host granular hydrogels. (a) Schematic,
(b) frequency sweeps and (c) average storage (G’) and (G’’) across a range of
frequencies for granular hydrogels (red), microgel controls where cyclodextrin is omitted
(blue), and polymer controls where the adamantane is omitted (black). Statistical
significance was assessed relative to the granular hydrogel for the corresponding
modulus and frequency with * denoting p < 0.05 and # denoting p < 0.005.
In previously developed hydrogels, guest-host crosslinking imparted shearthinning and self-healing properties rendering them injectable; thus, we investigated the
granular hydrogel behavior using a series of high (500%) and low (1%) strain cycles to
simulate the conditions of injection (Figure 6.6a). Granular hydrogels maintained high
mechanics (G’ ~6 kPa) under low strain conditions and then rapidly adopted fluid-like,
low mechanics (G’ ~100 Pa) under high strain. After returning to low strain, the hydrogel
returned to the initial, solid-like state before the next measurable time point (i.e. < 6 s)
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with similar mechanics (G’ ~6 kPa). This suggests that these materials undergo shearthinning and self-healing that makes them amenable for syringe injections.
This behavior was also observed in strain sweeps where increasing strain
transitioned the hydrogel from a more elastic solid to more viscous liquid behavior
(Figure 6.6b). Interestingly, a peak in the loss modulus was observed for the granular
hydrogel during yield (~30%) strain. We hypothesize that this is related to a
rearrangement of microgels as the material transitions towards a more fluid-like state.
Functionally, these granular hydrogels could be injected via needles as small as 27 G
(~210 µm inner diameter) into dry or aqueous environments with minimal extravasation
and without the need for long cure times or other stabilizing reactions (Figure 6.6c).

High Strain

b

High Strain

a

c

Figure 6.6. Shear-thinning behavior of granular hydrogels. (a) Strain-cycle
experiment for granular hydrogels, whereby materials are cycled between 1% and 500%
(shaded) strains. (b) Strain sweep analysis of granular hydrogels, indicating yielding
behavior at high strains. (c) Ejection of a guest-host granular hydrogel from a syringe
through a 27 G needle onto a dry surface.
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6.3.3.

MULTIPLEXED,

MULTIFUNCTIONAL

PROPERTIES

OF

GRANULAR

HYDROGELS
One advantage to the design of the granular hydrogels is that microgels of
various compositions (e.g., degradation, release profiles of encapsulated molecules) can
be included, either as separate formulations or even combined into a single injectable
system.

Generally, the variable properties of the microgels can be tailored through

altering the crosslinker chemistry. To explore this, we altered the di-thiol crosslinker
used for intra-particle covalent crosslinking to be either non-degradable (DTT), to
generate microgels that will subsequently be referred to as stable microgels, or matrix
metalloproteinase

(MMP)

cleavable

through

inclusion

of

a

peptide

(GCNSGGRMSMPVSNCG, Figure 6.7a) that incorporates multiple cysteines to present
thiols and an MMP-cleavable domain, to generate microgels that will subsequently be
referred to as cleavable microgels.

a

b

c

Figure 6.7. MALDI-TOF spectroscopy of synthesized peptides. (a) MMP cleavable
peptide (GCNSVPMSMRGGSNCG) m/z: expected 1601, found 1611. (b) Fluorescein
peptide (GCKK-FITC) m/z: expected 890, found 935 (corresponding to two Na ion
complex). (c) Rhodamine peptide (GCKK-RHO) m/z: expected 903, found 904.

Stable or cleavable microgels containing a rhodamine labeled dextran (RHODEX) or FITC-BSA payload, respectively, were formed into single-component granular
hydrogels and release of the payload and the hydrogel degradation (via uronic acid
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assay) were monitored over two weeks. Studies were performed either in PBS buffer
alone or containing 200U/mL collagenase to investigate the microgel response to
proteases. Single component stable and single component cleavable hydrogels
appeared as a mosaic of red or green microgels, respectively, when imaged on confocal
microscopy. Some non-uniformity in microgel fluorescence was observed, likely a result
of diffusion of the fluorescent materials. Over the course of two weeks, the cleavable
granular gels released their payload significantly faster in the presence of collagenase
(Figure 6.8a) and degraded more quickly (Figure 6.8b) when compared to the same
formulation in buffer alone. Comparatively, the stable formulation maintained similar
release profiles (Figure 6.8c) and degradation behavior (Figure 6.8d) regardless of
inclusion of collagenase in the release buffer. These data suggest that the choice of
microgel crosslinker provides a simple approach to control granular gel response and
encapsulated molecule release behavior.
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a

c

b

d

Figure 6.8. Molecule release and degradation of single-component granular
hydrogels. (a) FITC-BSA release and (b) degradation of granular hydrogels fabricated
from cleavable microgels with (+) or without (-) 200 U/ml collagenase included in the
buffer. (c) RHO-DEX release and (d) degradation of granular hydrogels fabricated from
stable microgels with (+) or without (-) 200 U/ml collagenase included in the buffer.
Degradation behavior was monitored through uronic acid release (n=3). Scale bar =100
µm.
We then sought to investigate more complex hydrogels by combining multiple
microgels into a single granular hydrogel. The advantage of the mixed microgel system
is the complexity that is obtained through the design, where features such as controlled
release of multiple factors and controlled cellular invasion are obtained with a single
hydrogel. We created a two-component granular hydrogel by mixing equal amounts of
stable and cleavable microgels containing RHO-DEX and FITC-BSA, respectively.
Microgels of varied composition were fabricated on separate devices, but potentially
devices could be generated in the future to simultaneously fabricate and mix microgel
populations on-chip. Visually, these materials contained distinct red, stable microgels
and green, cleavable microgels mixed together in a mosaic pattern (Figure 6.9a).
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When two-component hydrogels were probed for release, an accelerated rate of
FITC-BSA release was observed in the presence of collagenase, while profiles of RHODEX remained approximately similar either with or without collagenase (Figure 6.9b).
This result is in agreement with how each of the individual microgels behaved in singlecomponent systems. Furthermore, material degradation rates in the two-component
systems in the presence of collagenase fell in between single component stable and
single component cleavable systems, as expected due to the combination of microgel
populations (Figure 6.9c). Taken together, these data showed both visually and
functionally, that two-component systems combined the properties of each of the
previous single-component systems, suggesting that modular exchange of microgel
types is a successful means to independently multiplex functionality into these granular
hydrogels. Although only two components were investigated here, a higher number of
microgel compositions could be easily introduced.

Additionally, passive release of

encapsulated molecules could be minimized with alterations in microgel crosslink density
or through the incorporation of binding agents between the microgel and entrapped
molecule. The specific molecules and release profiles incorporated into the design will
depend on the biomedical application targeted.
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Figure 6.9. Molecule release and degradation of multi-component granular
hydrogels. (a) Confocal image (cross-sectional (left) and top (right) views) of twocomponent granular hydrogels containing cleavable microgels with encapsulated FITCBSA (green) and stable microgels containing RHO-DEX (red). (b) FITC-BSA and RHODEX release and (c) degradation of two-component granular hydrogels with (+) or
without (-) 200 U/ml collagenase included in the buffer. Degradation behavior was
monitored through uronic acid release (n=3). Scale bar =100 µm.
6.3.4. IN VIVO DEGRADATION AND CELL INVASION OF GRANULAR HYDROGELS
Myocardial infarction (MI) involves a complex sequence of tissue level changes,
including inflammation and elevated protease activity, cell death, and fibrosis.26,27 These
processes ultimately contribute to expansion of the left ventricle, thinning of the
myocardial wall, a loss of efficient ventricular mechanics and eventual heart failure.28
Injectable hydrogels are finding widespread use for the treatment of MI, particularly to
provide mechanical support or deliver therapeutics (e.g., drugs, cells) to the myocardium
during the remodeling process to improve outcomes.29,30 Emerging knowledge in this
field suggests that this manner of intervention can be time and disease dependent,
requiring control over material presence and drug release to optimally address
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therapeutic and mechanical targets.10,31 Multifunctional materials may be able to address
this cascade of events, through multiplexing properties that facilitate spatiotemporal
delivery of a variety of drugs and/or the manipulation of appropriate cell infiltration.
As elevated protease activity is a hallmark of MI, we sought to utilize diseasestate protease levels within MI to investigate a responsive two-component granular
hydrogel. In order to track these materials without the limitations of using encapsulated
fluorophores, we covalently labeled MMP-cleavable microgels with a FITC-tagged
thiolated peptide (GCKK-FITC,) and stable microgels with a RHO-tagged thiolated
peptide (GCKK-RHO) in situ during the microdevice-based microgel synthesis (Figure
6.7b,c). Granular hydrogels were then formed containing equal amounts of cleavable
and stable microgels and injected into the myocardial wall of either healthy rats or rats
having undergone MI. Animals were serially sacrificed after one, two, or three weeks, at
which point the hearts were explanted and preserved in optimal cutting temperature
compound. Cardiac tissue was sectioned and imaged using a confocal microscope
(Figure 6.10).
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Figure 6.10. Disease dependent behavior of two-component granular hydrogels.
Two-component granular hydrogels labeled with FITC for cleavable microgels and
rhodamine for stable microgels were injected into rat hearts either without myocardial
infarction (no MI) or with MI. Representative images of microgels and cell nuclei (blue) at
one, two, and three weeks after injection (scale bar = 500 µm).
At one week, cleavable microgels in tissue sections were a mixture of spherical
and degraded morphologies, with the MI group displaying more advanced degradation in
microgel morphology (Figure 6.10). At two weeks, much of the cleavable material was
cleared in the MI condition, while large aggregates of partially degraded microgels
remained in the healthy condition. Finally, at the three-week time point, there was little
remaining cleavable material in either condition. Across all conditions, stable microgels
remained present with spherical, non-degraded morphologies throughout the duration of
the three-week study.
Microgel presence was quantified at the two week timepoint, due to stark visual
differences in microgels at this timepoint, by measuring the fluorescence intensity and
area of both microgel types and normalizing to the total injection site area, in order to
provide a metric of material mass and volume in the injection site (Figure 6.11a).
Cleavable material normalized fluorescence intensity in the MI condition was ~40% of
the no MI condition and cleavable material normalized area was ~20% of the normalized
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area in the no MI condition. This indicated preferential degradation of cleavable
microgels in the MI condition. There were no significant differences in stable microgel
fluorescence intensity in the no MI condition. Relative to the no MI condition, there was a
small decrease in the amount of stable normalized microgel area in the MI group,
possibly indicating increased dispersion of the stable microgels in the tissue after MI,
likely due to increased cellular invasion as the cleavable microgels were degraded
(Figure 6.11b).
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Figure 6.11. Quantification of microgel degradation in vivo. (a) Quantification of
remaining microgels at 2 weeks, as (a) fluorescence intensity normalized to the injection
site area or (b) area of microgel to injection site area (n=3). Statistical significance was
assessed relative to healthy controls with p < 0.05.
Because proteases are elevated during MI, but still maintain a baseline presence
in healthy tissue, we would expect that protease degradable microgels would eventually
degrade in both healthy and MI conditions; however, the rates would be significantly
different. These data suggest that the elevated MMP activity following an infarction is
responsible for significantly accelerating the degradation of the protease cleavable
microgels in the two-component granular hydrogel.
Further to differences in degradation, these materials facilitated cell infiltration,
due to their highly porous, dynamic nature and this is in agreement with other results
found in granular systems.22 Through both DAPI (Figure 6.10) and hematoxylin and
eosin staining (Figure 6.12), we observed cellularization within all conditions across the
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timepoints; however, accelerated cellularization was observed at earlier time points in
the MI condition concomitant with the more rapid degradation of the cleavable
component of the dual-microgel system. For the MI conditions, large, vacated pores that
we believe are a result of cleavable microspheres degrading were observed as early as
one week and cellularity then increased with time.

For the no MI condition, less

cellularization was observed at the early times, but cellularity also increased with time,
albeit at a slower pace when compared to the MI condition with elevated protease levels.
In the context of MI, these findings are important as protease activity is a significant
biological handle to signal disease-dependent material response. Beyond MI, elevated
MMP activity is a key signal for smart biomaterial approaches during other conditions
such as inflammation and cancer, making this approach broadly impactful in a number of
diseases.

2 weeks

3 weeks

No MI

MI

1 week

Figure 6.12. Hematoxylin and eosin staining. Hematoxylin and eosin staining of MI
and no MI tissue sections at one week, two weeks, and three weeks. Scale bar = 500
µm.
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6.3.5. FUNCTIONAL STUDIES OF GRANULAR HYDROGELS DELIVERING SDF-1α
As we observed controllable degradation and cellular invasion in these materials
in response to disease states, we considered that granular hydrogel injection may also
influence cardiac function. Indeed, it has been observed previously that particle-based
systems in the myocardium can influence functional outcomes in the myocardium
through tissue bulking and alteration of the inflammatory response.

32,33

Additionally,

towards controlling cell type in the myocardium, and providing therapeutic delivery, we
designed the granular hydrogel system for the delivery of therapeutics; specifically, SDF1α was encapsulated into microgels, as SDF-1α has been previously shown to be useful
in the myocardium as a therapeutic for recruiting stem cells and influencing biological
outcomes such as vascularization. 34
SDF-1α was encapsulated in cleavable microgels to provide early, disease
dependent delivery to recruit stem cells to the infarct. We assayed release of SDF-1α
using an ELISA kit in the presence of 500 U/mL collagenase, and observed release of
SDF-1α over approximately two weeks (Figure 6.13). This aligned well with the goal of
early recruitment of cells. Because stable particles themselves have previously shown
functional benefit in MI models, we formulated a granular system as done previously,
containing cleavable particles either empty or loaded with SDF-1α, as well as stable
particles. Wistar rats received infarcts and were treated with either PBS (PBS, n = 15),
blank granular gels (Gel, n = 7), or granular gels loaded with SDF-1α (Gel/SDF, n = 7).
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Figure 6.13. Release of SDF-1α from granular hydrogels. Granular hydrogels of the
formulation investigated previously loaded with SDF-1α contained in cleavable microgels
were incubated in the presence of 200 U/mL collagenase as a means to replicate the
proteolytic infarcted myocardium. Supernatant was sampled and collected over 4 weeks,
and releaseates were analyzed for SDF-1α content using an ELISA kit.
When investigating the functional outcomes, it was observed that only the
granular hydrogel delivering SDF-1α had a significantly improved ejection fraction over
the PBS control (Figure 6.14a). Both granular hydrogel groups (with and without SDF1α) groups showed significant improvements in cardiac output, as well as dP/dtmax, a
measure of cardiac contractility as compared to PBS controls (Figure 6.14b,c).
Surprisingly, the granular hydrogel treatments did not improve volumes after treatment
(Figure 6.14d,e). It is likely that both granular materials are influencing the myocardium
by providing a means of cellular invasion and bulking, as has been demonstrated
previously with numerous hydrogel systems and one treatment group improved
outcomes with SDF delivery by altering local cellularity.
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Figure 6.14 Functional outcomes at 4 weeks after MI. (a) Ejection fraction, (b) cardiac
output, (c) dp/dtmax, (d) left ventricle end-systolic volume (LVESV), and (e) left ventricle
end-diastolic volume (LVEDV) for animals treated with PBS (n=15, blue), granular
hydrogels (gel, n=7, red), or granular hydrogels loaded with SDF (gel/SDF, n=7, green).
Statistical significance was assessed using a one-way ANOVA with post hoc Tukey
testing with * representing p<0.05 against PBS control group.
The biological role of particle based material systems in the myocardium has
been investigated through the implantation of dermal fillers, as well as hyaluronic
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acid/PLGA microsphere composites.

32,33

These systems have been shown to stimulate

the inflammatory response in a unique way to induce beneficial stabilization to the infarct
through ECM production as well as vasculogenesis, ultimately leading to improved
outcomes including scar fraction and functional benefits. Particles in these systems fell
into a unique size regime (>10µm, <100µm) that mitigates fibrous capsule formation, but
prevents macrophage phagocytosis. Granular hydrogels developed here utilized
microgels of a similar size regime to microgels. To better understand the biological
response to the injected granular hydrogels, markers for inflammation, cell receptors,
and vascularization were investigated using immunohistochemical analysis (Figure
6.15a). Analysis of the inflammatory state of the myocardium local to injection sites
shows that both gel groups and gel/SDF groups have significantly elevated macrophage
levels as compared to PBS control groups (Figure 6.15b). This is likely a result of the
granular nature of these materials, as previous studies investigating PLGA microsphere
implants in the myocardium have shown elevated pro-healing, and overall inflammatory
response.

33

While elevated inflammatory response is often thought to be detrimental in

implanted materials, the potential for increased collagen deposition and vascularization
generating stabilization of the infarcted tissue in the myocardium could provide
significant benefit in acute phase MI.
We further explored the biological function of SDF-1α

delivery from granular

hydrogels. To this end, we stained tissue sections for the presence of CXCR4, the cell
receptor for SDF that is often present on recruited cells. Gel/SDF treatment groups
showed significantly higher CXCR4+ cell counts as compared to either PBS or gel
treatments without SDF, suggesting that SDF delivery was in fact localizing stem cells to
the myocardium in this system (Figure 6.15c).
Finally, we evaluated vascularization as a further downstream biological process
of both macrophage invasion and stem cell recruitment. Areas of colocalized regions

161	
  

staining positive for isolectin and αSMA were quantified. Only the Gel/SDF treatment
group showed significant increase in this area as compared to PBS controls, indicating
that SDF was critical to stimulating vasculogenesis in these systems. (Figure 6.15d). In
summary, it is clear that granular hydrogels provide improved functional benefits to the
myocardium, play a role in altering macrophage response, and that SDF delivery from
these systems provides synergistic effect through the recruitment of stem cells to and
generation of microvasculature in the infarcted tissue.
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Figure 6.15. Immunohistochemistry for myocardial sections at 4 weeks after MI. (a)
Representative images of macrophage (CD68, magenta), migratory stem cells (CXCR4,
green), and vascular (isolectin, green and αSMA, red) staining. All images are co-stained
with DAPI (blue). Scale bar represents 200µm. (b) CD68+ area fraction, a marker of
macrophage activity, (c) CXCR4+ cells, a marker of miratory stem cells induced by SDF,
and (d) isolectin/ αSMA co-stained area, a marker of microvasculature determined in
regions local to microparticle injections at the border zone of MI. Statistical significance
was assessed using a one-way ANOVA with post hoc Tukey testing with * representing
p<0.05 against PBS control group, and # representing p<0.05 against Gel group.
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6.4. CONCLUSIONS
In conclusion, we developed an injectable granular hydrogel, using guest-host
interactions. This hydrogel displayed shear-thinning and self-healing properties that
rendered it amenable to injection into dynamic environments and abrogated the need for
controlled working/cure times that are often associated with other crosslinking
mechanisms. The granular structure of this material allowed for multiplexing of complex
release and degradation profiles that could be adjusted through modular exchange of
intra-particle crosslinking or through combining multiple microgel types. The multiplexed
material properties and high porosity of two-component granular hydrogels provided for
unique disease-dependent behavior and high levels of cell invasion after injection into
myocardial tissues. Finally, these materials were able to deliver the chemokine SDF-1α
to improve cardiac function and biological outcomes.
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CHAPTER 7

CONCLUSIONS, LIMITATIONS, AND FUTURE DIRECTIONS

7.1. OVERVIEW
Work presented in this dissertation shows the development, characterization, and
application of guest-host (GH) interactions in designing hydrogels with properties that
are appropriate for biomedical applications. As described in Chapter 3, biomaterial
systems based on this class of interactions are finding broad use in the fields of drug
delivery, cell delivery, material implants, and even towards basic science applications.1
Specifically, hydrogels engineered with GH interactions have been useful in the context
of myocardial infarction (MI), as outlined in Chapter 1, largely due to their ability to be
injected into tissues.2-4 Through further engineering, this thesis expands the application
of GH hydrogels to MI, by incorporating small molecule delivery or through multiplexing
design where properties such as degradation, delivery, and cell invasion are included in
a single system.5
More specifically, Chapter 4 described utilizing the reversible nature of
cyclodextrin GH chemistry to tune small molecule sustained release for a number of
model payloads as well as representative small molecule pharmaceuticals.6 Chapter 6
described the development of granular hydrogels, formed through GH mediated
assembly of microgel components, that allowed for the modular combination of different
populations of microgels (each with different material design parameters, e.g.
degradation, payload, etc) into a single bulk, injectable material with multifunctional
properties.7 Both of these advances in material design were then applied in models of
MI. Chapter 5 described the design of GH hydrogels for the sustained release of
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SD7300, an MMP inhibitor that requires local delivery, and the application of the
hydrogel system to a porcine model of MI with clinically relevant timing and
percutaneous delivery. Additionally, work at the end of Chapter 6 outlined the potential
efficacy of multifunctional granular materials in treatment of MI, with a capacity for
disease responsive behavior and tunable cell invasion properties. The remainder of this
chapter will focus on the main conclusions, limitations, and future directions associated
with each of these aims.

7.2. SPECIFIC AIM 1
DESIGN AN EASILY INJECTABLE GUEST-HOST HYDROGEL FORMULATION FOR
SUSTAINED SMALL MOLECULE DELIVERY

7.2.1. CONCLUSIONS
In this aim, we were able to demonstrate the ability of cyclodextrin to modify the
affinity of HA polymers for small molecules through the use of analytical calorimetric
methods. When assembled into hydrogels through GH interactions, the inclusion of
cyclodextrin altered the diffusion and bulk release of encapsulated peptides.

We

determined that these outcomes were tunable based on two key parameters: the level of
cyclodextrin content in the GH hydrogels and the payload affinity for cyclodextrin. The
mechanical properties of these materials were not greatly influenced by the
encapsulation of small molecules, likely due to the higher relative affinity of cyclodextrin
for adamantane, the interaction driving polymer association in this system. Ultimately,
we were then able to use these parameters as a means to provide tunable sustained
release of small molecule antibiotics and chemotherapeutics. This work has expanded
the capabilities of injectable hydrogel systems to easily incorporate small molecule
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sustained release, an important class of therapeutics that frequently require carriers
such as these injectable hydrogels for efficacy.

7.2.2. LIMITATIONS AND FUTURE DIRECTIONS
Material systems developed in this chapter lay a foundation for simple strategies
to provide sustained small molecule release from biomaterials; however, there are
numerous instances where the findings could be expanded with further material iteration.
Specifically, the studies were confined to the investigation of one host molecule
(cyclodextrin) and only a handful of different guest molecules. Thus, the observed scope
of the effects on sustained release remains somewhat limited. While this selection of
host molecule was highly useful, due to the GRAS classification of cyclodextrin and its
general use as a pharmaceutical excipient, it is possible that investigation of other host
molecules such as cucurbits, etc could provide an even more pronounced effect on
sustained release.8,9 Furthermore, while we observed no significant effects of molecule
encapsulation on material mechanics in the system investigated, it is possible that
through competitive binding, small molecules with high affinity for cyclodextrin (i.e.
approaching that of adamantane) could alter hydrogel mechanical properties.
Towards future studies, one important advance would be modeling to predict
release profiles for small molecules encapsulated in GH hydrogels. In the case of other
material systems such as PLGA microspheres, it is often simple to predictively
generalize release profiles since release is largely controlled by material degradation
and structure, and is largely independent of the nature of the selected payload.10,11 Our
experience with these systems is that release is not only controlled by material
parameters (e.g., concentration, extent of modification), but also the specific interaction
between material and payload, making it difficult to predictively generalize release
profiles, although some groups have taken steps towards this in protein-based
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systems.12 Particularly with cyclodextrins, there is a wealth of molecule affinity data that
could be directly integrated to a predictive modeling approach, or data that could be
gathered using modeling software of molecular interactions.13 Within models, variations
in parameters such as host (cyclodextrin) concentration, guest (adamantane)
concentration, drug concentration, and drug-host affinity, would be useful to
quantitatively determine their effect on release in silico to guide the design of GH
hydrogel formulations for future small molecule release.

7.3. SPECIFIC AIM 2
RELEASE A SMALL MOLECULE PROTEASE INHIBITOR FROM AN INJECTABLE
GH HYDROGEL FOR TREATMENT OF MI

7.3.1. CONCLUSIONS
In this aim, we were able to design GH hydrogels as easily injectable materials
for sustained SD-7300 release. First, we screened material formulations to assess
shear-thinning properties to determine a formulation that balanced shear-thinning for
injection, mechanical properties for deposition into tissue, and cyclodextrin content for
SD-7300 retention. We determined a formulation that was easily injectable based on
injection force testing, and assayed it for SD-7300 release. Hydrogels with encapsulated
SD-7300 had sustained release over several weeks and showed MMP-2 inhibitory
activity over this entire period, a timeline that is concurrent with the acute phase of MI.
When investigated in a porcine MI model of ischemia-reperfusion, GH hydrogels could
be injected and retained in the myocardial wall and localized small molecules to this
region Animals received injections 3-5 days after MI of hydrogels containing SD-7300
with hydrogels or PBS injections alone used as controls. Gel/SD7300 treatment
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improved functional outcomes such as ejection fraction, as well as histological outcomes
including MI area and collagen content when compared to hydrogel or PBS injection
alone. Thus, GH hydrogels were able to successfully sustain the release of SD-7300 to
provide therapeutic efficacy in a clinically relevant, delayed injection animal model.

7.3.2. LIMITATIONS AND FUTURE DIRECTIONS
This study showed the development of GH hydrogels for the sustained release of
SD-7300, and application in a porcine model of MI. As a pre-clinical model, this study
was translationally focused, incorporating an ischemia-reperfusion infarct as well as
delayed injection of hydrogels, both features that represent more common infarct and
treatment scenarios in patients. This study, however, is not without limitations. This
study was limited through necessary design choices in both materials and animal
models. While logistically challenging to complete, a number of dosing studies are
necessary to optimize both drug dosing and material volumes in the myocardium for
specific drugs and material formulations. In depth clarification of these parameters will
help to clarify the interplay between material bulking, and the biological effects targeted
by therapeutic payloads such as SD-7300. Further developments of catheter/injection
systems are needed, to provide assurance in the safety of material injection, to limit any
risk of embolism upon ventricular injection of this material. This could include catheterbased or helical needle injections to afford surgeons increased control over material
placement in the myocardial wall. Further, the scope of this project was confined to one
inhibitor at a 3-day delayed timepoint.
Both timing of material injections and MMP inhibitor subtype have been shown to
play a critical role in MI, often with optimal windows for material injection and specific
MMP inhibition.14-16 Future directions for this work could investigate the inhibitor
treatment at a range of different injection time-points, to evaluate further efficacy of the
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therapy. All studies completed here evaluated relatively short (~4 weeks) time points
after infarct and administration of treatment for structure and function. As the effects of
these therapies influence the long term progression of heart failure, it is important to
consider analysis of much longer time points (i.e. months to years) after MI and
treatment to gain a full understanding of the impact of these systems.

7.4. SPECIFIC AIM 3
DEVELOP AN INJECTABLE GRANULAR HYDROGEL SYSTEM FOR TREATMENT
OF MI
7.4.1. CONCLUSIONS
In this aim, we showed the design of granular hydrogel systems that were
injectable through the incorporation of GH chemistry. Microgels with adamantane
chemistry were formed using a microfluidic approach that is scalable to high throughput
production. These particles were assembled using CD-HA into brick and mortar type
structures that were visualized using confocal microscopy. Furthermore, the mechanical
properties of these systems were dependent on GH interactions between particles and
CD-HA polymer incorporated into the system. Granular hydrogels developed in this aim
were shear-thinning and self-healing, and were injectable through needles as small as
28 G. Through the design of intra-particle covalent crosslinking chemistry and payload
encapsulation, particles were designed to encapsulate a range of payloads that released
under a variety of conditions. These particle populations were combined into a single
granular hydrogel, which represented the behavior of the specific microgel compositions
(payload, release profile).
Multifunctional granular hydrogels were injected into infarcted and healthy
myocardium in rats, and displayed disease responsive and disease independent
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behavior in subpopulations of microgels in these systems. Furthermore, the granular
nature of these materials allowed for high degrees of cell invasion, which is also
dependent on particle design and disease interaction. Cell-material interactions are
critical in this context, as cell invasion and the subsequent stimulation of inflammatory
processes such as collagen deposition and vasculogenesis are beneficial to stabilizing
the infarcted myocardium. In rat MI studies, we showed that granular systems
themselves provide functional benefits, likely by influencing macrophage response and
stabilizing the infarct through this response, as has been seen in previous studies.17
Furthermore, we controlled cells invading the myocardium, by delivering the chemokine
SDF-1α from an individual microgel component. Materials loaded with this chemokine
were able to provide increased recruitment of CXCR4+ cells to the myocardium, and
showed improved benefit in ejection fraction. This microgel system provides a platform
for investigation of numerous therapeutic molecules to treat MI.

7.4.2. LIMITATIONS AND FUTURE DIRECTIONS
Materials developed in this aim provided a new avenue for material design by
multiplexing material properties into a single system with controllable bulk mechanical
properties for injection. Studies conducted in this aim do have several limitations. Animal
studies in this aim were conducted in small animal models. While these studies are
beneficial for throughput and gaining insight into material behavior in an in vivo context,
there are limitations to testing myocardial injections in small animals. Due to the injected
volumes of hydrogel in the rat myocardium, it is likely that in addition to the biological
roles of these systems described in chapter 6, these granular systems are exerting a
major effect through cardiac bulking. Furthermore, these systems were delivered
concurrently with the generation of infract, which itself was a permanent ligation of
cardiac vasculature. These approaches in an animal model are not representative of the
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conditions these systems would experience in a clinical setting, in terms of both injection
timing and potential tissue perfusion. Moving towards analysis in large animals can help
to clarify the interplay between tissue bulking, cell invasion and vasculogenesis, and the
effect of delivered payloads such as SDF.
These studies have also only shown early proof of concept for the use of
granular systems as drug delivery depots. Due to the ease of combining numerous
payloads, release rates, and degradation properties, these materials would make an
excellent platform for complex drug delivery problems involving synergistic release of
multiple payloads. Prior work has shown the benefits of delivering multiple factors to the
myocardium associated with vasculogenesis, however, this could be expanded to
introduce further targets such as cell recruitment and MMP inhibition.18 Furthermore, this
system lends itself to complex release profiles, which could be useful in timing-critical
delivery challenges such as in vivo cell reprogramming, a process requiring sequential
delivery of numerous factors.19
A final limitation of this work is that the scope of these materials was confined to
the design of ~40 µm diameter microgel particles. The role of particle size could be
investigated in future studies to determine the effect on both material mechanical
properties, as well as induction of in vivo cell invasion and ECM deposition. Finally, the
utility of these materials could be further expanded to basic science studies in cell
culture and mechanobiology.

7.5. OVERALL SUMMARY
Overall, broad conclusions of this dissertation relate to the development of novel
biomaterial function through the utilization of GH chemistry, and the application of these
materials for myocardial infarction therapies. Through material design, we were able to
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generate unique hydrogel systems that could deliver small molecules or provide
combinatorial functionality. These platform systems are broadly compatible with a range
of molecules for drug delivery, providing future potential investigating translational
challenges such as the local delivery of small molecules, or more academic pursuits
clarifying the nature of timing, and synergistic therapies in drug delivery strategies for MI.
Hydrogel systems for drug delivery have enormous potential as an emerging class of
therapeutics in the myocardium. As an understanding of the effects of biomaterials in the
myocardium matures, studies and materials such as the ones of this thesis will form the
groundwork for translation and solving clinical delivery challenges.

7.6. REFERENCES
1.

Rodell CB, Mealy JE, Burdick JA. Supramolecular guest–host interactions for the
preparation of biomedical materials. Bioconjugate chemistry. 2015;26(12):227989.

2.

Rodell CB, Lee ME, Wang H, Takebayashi S, Takayama T, Kawamura T, et al.
Injectable Shear-Thinning Hydrogels for Minimally Invasive Delivery to Infarcted
Myocardium to Limit Left-Ventricular Remodeling. Circulation Cardiovascular
interventions. 2016;9(10).

3.

Rodell CB, MacArthur JW, Dorsey SM, Wade RJ, Wang LL, Woo YJ, et al.
Shear-Thinning Supramolecular Hydrogels with Secondary Autonomous
Covalent Crosslinking to Modulate Viscoelastic Properties In Vivo. Adv Funct
Mater. 2015;25(4):636-44.

4.

Tous E, Purcell B, Ifkovits JL, Burdick JA. Injectable acellular hydrogels for
cardiac repair. J Cardiovasc Transl Res. 2011;4(5):528-42.

177	
  

5.

Hoare TR, Kohane DS. Hydrogels in drug delivery: Progress and challenges.
Polymer. 2008;49(8):1993-2007.

6.

Mealy J, Rodell C, Burdick JA. Sustained Small Molecule Delivery from Injectable
Hyaluronic Acid Hydrogels through Host-Guest Mediated Retention. Journal of
Materials Chemistry B. 2015.

7.

Mealy JE, Chung JJ, Jeong HH, Issadore D, Lee D, Atluri P, et al. Injectable
Granular Hydrogels with Multifunctional Properties for Biomedical Applications.
Adv Mater. 2018;30(20):1705912.

8.

Loftsson T, Brewster ME. Pharmaceutical applications of cyclodextrins: basic
science and product development. J Pharm Pharmacol. 2010;62(11):1607-21.

9.

Ma D, Hettiarachchi G, Nguyen D, Zhang B, Wittenberg JB, Zavalij PY, et al.
Acyclic cucurbit [n] uril molecular containers enhance the solubility and bioactivity
of poorly soluble pharmaceuticals. Nature Chemistry. 2012;4(6):503-10.

10.

Rothstein SN, Federspiel WJ, Little SR. A unified mathematical model for the
prediction of controlled release from surface and bulk eroding polymer matrices.
Biomaterials. 2009;30(8):1657-64.

11.

Rothstein SN, Federspiel WJ, Little SR. A simple model framework for the
prediction of controlled release from bulk eroding polymer matrices. J Mater
Chem. 2008;18(16):1873-80.

12.

Vulic K, Pakulska MM, Sonthalia R, Ramachandran A, Shoichet MS.
Mathematical model accurately predicts protein release from an affinity-based
delivery system. J Control Release. 2015;197:69-77.

13.

Rekharsky MV, Inoue Y. Complexation Thermodynamics of Cyclodextrins. Chem
Rev. 1998;98(5):1875-918.

178	
  

14.

Yoshizumi T, Zhu Y, Jiang H, D'Amore A, Sakaguchi H, Tchao J, et al. Timing
effect of intramyocardial hydrogel injection for positively impacting left ventricular
remodeling after myocardial infarction. Biomaterials. 2016;83:182-93.

15.

Iyer RP, de Castro Brás LE, Patterson NL, Bhowmick M, Flynn ER, Asher M, et
al. Early matrix metalloproteinase-9 inhibition post-myocardial infarction worsens
cardiac dysfunction by delaying inflammation resolution. J Mol Cell Cardiol.
2016;100:109-17.

16.

Iyer RP, Patterson NL, Zouein FA, Ma Y, Dive V, de Castro Brás LE, et al. Early
matrix metalloproteinase-12 inhibition worsens post-myocardial infarction cardiac
dysfunction by delaying inflammation resolution. International journal of
cardiology. 2015;185:198-208.

17.

Tous E, Weber HM, Lee MH, Koomalsingh KJ, Shuto T, Kondo N, et al. Tunable
hydrogel-microsphere composites that modulate local inflammation and collagen
bulking. Acta Biomater. 2012;8(9):3218-27.

18.

Awada HK, Johnson NR, Wang Y. Sequential delivery of angiogenic growth
factors improves revascularization and heart function after myocardial infarction.
J Control Release. 2015;207:7-17.

19.

Buganim Y, Faddah DA, Jaenisch R. Mechanisms and models of somatic cell
reprogramming. Nature Reviews Genetics. 2013;14(6):427.

179	
  

